All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:19:51 ON 15 DEC 2006

=> file uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'USPATFULL' ENTERED AT 11:20:12 ON 15 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 14 Dec 2006 (20061214/PD)
FILE LAST UPDATED: 14 Dec 2006 (20061214/ED)
HIGHEST GRANTED PATENT NUMBER: US7150045
HIGHEST APPLICATION PUBLICATION NUMBER: US2006282930
CA INDEXING IS CURRENT THROUGH 12 Dec 2006 (20061212/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 14 Dec 2006 (20061214/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

=> s us2004/0167165/pn
L1 1 US2004/0167165/PN
(US2004/PN)

=> d rn

L1 ANSWER 1 OF 1 USPATFULL on STN

=> d rn

L1 ANSWER 1 OF 1 USPATFULL on STN

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.43	1.64

FILE 'CAPLUS' ENTERED AT 11:20:44 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

```
FILE COVERS 1907 - 15 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 14 Dec 2006  (20061214/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us2004/0167165/pn
L2            0 US2004/0167165/PN
                (US2004/PN)

=> s edg-7 receptor
            945 EDG
             25 EDGS
            960 EDG
                (EDG OR EDGS)
        2724212 7
         679155 RECEPTOR
         623140 RECEPTORS
         808489 RECEPTOR
                (RECEPTOR OR RECEPTORS)
L3            7 EDG-7 RECEPTOR
                (EDG(W)7(W)RECEPTOR)

=> d ibib abs 1-7

L3   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1242755  CAPLUS
DOCUMENT NUMBER:          143:472565
TITLE:                    Methods of treating conditions associated with an
                          Edg-7 receptor
INVENTOR(S):              Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet
                          V.; Gluchowski, Charles
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S.
                          Ser. No. 352,579.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2005261298         A1    20051124    US 2003-390428          20030314
     WO 2003062392         A2    20030731    WO 2003-US1881          20030121
     WO 2003062392         A3    20050120
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                    US 2002-350446P     P  20020118
                                          WO 2003-US1881      A1 20030121
                                          US 2003-352579      B2 20030127
                                          US 2002-350445P     P  20020118
                                          US 2002-350447P     P  20020118
                                          US 2002-350448P     P  20020118
```

OTHER SOURCE(S): MARPAT 143:472565
AB In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703129 CAPLUS
DOCUMENT NUMBER: 141:218996
TITLE: Methods using Edg-7 modulators for treating conditions associated with an Edg-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167192	A1	20040826	US 2004-760002		20040116
PRIORITY APPLN. INFO.:			US 2003-440321P	P	20030116
			US 2003-454881P	P	20030313

OTHER SOURCE(S): MARPAT 141:218996
AB The invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor-mediated biol. activity. The invention also provides a method for modulating an Edg-7 receptor-mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject. Preparation of e.g. 4-Bromo-2-[2-(4-chlorophenylamino)-4-oxothiazolidin-5-ylidenemethyl]phenoxyacetic acid is described.

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703124 CAPLUS
DOCUMENT NUMBER: 141:218944
TITLE: Treating conditions associated with an Edg-7 receptor
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167165	A1	20040826	US 2004-760062	20040116

PRIORITY APPLN. INFO.: US 2003-440336P P 20030116
OTHER SOURCE(S): MARPAT 141:218944
GI



I



II

AB The invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biol. activity. The invention provides a method for modulating an Edg -7 receptor mediated biol. activity in a subject. A therapeutically effective amount of the Edg-7 receptor modulator with formula I (where R1,R2 R3 R4 and R7 = -H,-halo,-CN, -NO2 etc. independently) or with formula II (where R1, R2, R3, R4 and R7 = -H,-halo, -NO2 -CN, etc.) or a pharmaceutically available solvate or hydrate therof is administered to the subject.

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:591307 CAPLUS
DOCUMENT NUMBER: 139:143997
TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): Ceretek LLC, USA
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473740	AA	20030731	CA 2003-2473740	20030121
AU 2003214873	A1	20030902	AU 2003-214873	20030121
EP 1513522	A2	20050316	EP 2003-710713	20030121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519915	T2	20050707	JP 2003-562260	20030121
US 2005261298	A1	20051124	US 2003-390428	20030314

PRIORITY APPLN. INFO.: US 2002-350445P P 20020118
US 2002-350446P P 20020118
US 2002-350447P P 20020118
US 2002-350448P P 20020118
WO 2003-US1881 W 20030121
US 2003-352579 B2 20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:133109 CAPLUS
DOCUMENT NUMBER: 138:147773
TITLE: Remedies for prostatic diseases
INVENTOR(S): Furuno, Masahiro; Naito, Takayuki; Yamamoto, Yoshihisa; Aoki, Junken; Arai, Hiroyuki; Kakehi, Yoshiyuki
PATENT ASSIGNEE(S): Japan Tobacco, Inc., Japan
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013605	A1	20030220	WO 2002-JP8016	20020806

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2001-239306 A 20010807
JP 2002-224215 A 20020731

AB It is intended to prevent and treat prostatic diseases. More specifically speaking, it is found out that the causes and mechanisms of the onset of prostatic diseases closely relate to interactions among LPA receptors expressed in epithelial cells and LPA serving as a ligand thereof and the interactions among various physiol. active substances thus secreted from the prostatic epithelial cells and prostatic interstitial cells; that prostatic interstitial cells proliferate owing to these interactions; and that a substance inhibiting the interactions between the LPA receptors and LPA inhibits the proliferation of prostatic cells. Based on these findings, there are provided medicinal compns. containing, as the active ingredient, a substance inhibiting intracellular signal transduction induced by stimulus mediated by Edg-7 receptor which is one of the LPA receptors and frequently expressed in prostatic epithelial cells. Using these compns., the signal transduction and

secretion of the physiol. active substances as described above are inhibited. It is intended that prostatic diseases can be thus prevented and/or treated.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:713600 CAPLUS
DOCUMENT NUMBER: 135:267219
TITLE: Synthesis of lysophosphatidic acid receptor agonists and antagonists and their use for cancer inhibition, wound healing, and enhancement of cell proliferation
INVENTOR(S): Miller, Duane D.; Tigyi, Gabor; Dalton, James T.; Sardar, Vineet M.; Elrod, Don B.; Xu, Huiping; Baker, Daniel L.; Wang, Dean; Liliom, Karoly; Fischer, David J.; Virag, Tamas; Nusser, Nora
PATENT ASSIGNEE(S): University of Tennessee Research Corporation, USA
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001071022	A2	20010927	WO 2001-US8729		20010319
WO 2001071022	A3	20020404			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2402038	AA	20010927	CA 2001-2402038		20010319
AU 2001049263	A5	20011003	AU 2001-49263		20010319
EP 1263752	A2	20021211	EP 2001-922465		20010319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004506604	T2	20040304	JP 2001-569403		20010319
PRIORITY APPLN. INFO.:			US 2000-190370P	P	20000317
			WO 2001-US8729	W	20010319

OTHER SOURCE(S): MARPAT 135:267219

AB The present invention relates to lysophosphatidic acid (LPA) analogs and cyclic derivs. of the analogs as well as pharmaceutical compns. which include those compds. Also disclosed are methods of using such compds., which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound. Thus, 2-amino-3-oxo-3-(tetradecylamino)propyl dihydrogen phosphate (I), 2-(acetylamino)-3-oxo-3-(tetradecylamino)propyl dihydrogen phosphate (II), and 1,2-(3-octadecyloxypropane)-bis(dihydrogen phosphate) (III) were synthesized. The cytotoxicity of these compds. on prostate cancer cell lines was determined The IC50's observed were 0.7 ± 0.1 for I on PC-3 cells, 0.7 ± 0.1 for II on DU145 cells, and 3.1 ± 3.2 for III on LNCaP cells. Addnl., phosphoric acid monododecyl ester (IV) was prepared and screened in Xenopus oocytes (which produce the PSP24 receptor) and in recombinant RH7777 cells producing Edg-2, Edg-4, and Edg-7 receptors. In Xenopus IV inhibited LPA-induced chloride currents with an IC50 value of about 8.1 nM. In Edg-2 and Edg-4-expressing RH7777 cells IV significantly inhibited the

Ca2+ responses while in Edg-7-expressing cells this compound increased the Ca2+ responses.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:223286 CAPLUS
DOCUMENT NUMBER: 133:132879
TITLE: Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate
AUTHOR(S): Im, Dong-Soon; Heise, Christopher E.; Harding, Michael A.; George, Susan R.; O'Dowd, Brian F.; Theodorescu, Dan; Lynch, Kevin R.
CORPORATE SOURCE: Departments of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA, USA
SOURCE: Molecular Pharmacology (2000), 57(4), 753-759
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Two G protein-coupled receptors (Edg-2) and (Edg-4) for the lysolipid phosphoric acid mediator lysophosphatidic acid have been described by mol. cloning. However, the calcium-mobilizing receptor Edg-4 is not expressed in some cell lines that exhibit robust calcium responses to this ligand, thus predicting the existence of addnl. receptor subtypes. A third human lysophosphatidic acid receptor subtype, Edg-7, which mediates lysophosphatidic acid-evoked calcium mobilization is now characterized. In a rat hepatoma Rh7777 cell line that lacks endogenous responses to lysophosphatidic acid, this lipid mediator, but not others, evokes calcium transients when the cells have been transfected with Edg-7 or Edg-4 DNAs. Furthermore, frog oocytes exhibit a calcium-mediated chloride conductance in response to mammalian-selective lysophosphatidic acid mimetics after injection of Edg-7 mRNA. Edg-7-expressing Rh7777 cells do not show inhibition of forskolin-driven rises in cAMP in response to lysophosphatidic acid. However, membranes from HEK293T cells cotransfected with Edg-7 and Gi2α protein DNAs show lysophosphatidic acid dose-dependent increases in [γ-35S]GTP binding with an EC50 value of 195 nM. When this assay was used to compare various synthetic LPA analogs at Edg-2, Edg-4, and Edg-7 receptors, ethanolamine-based compds., which are full LPA mimetics at Edg-2 and Edg-4, exhibit little activity at the Edg-7 receptor. Edg-7 RNA was detected in exts. of several rat and human tissues including prostate. Together, the data indicate that Edg-7 is a third lysophosphatidic acid receptor that couples predominantly to Gq/11α proteins.
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 1 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 569656-29-7 REGISTRY
ED Entered STN: 20 Aug 2003
CN 9H-Thioxanthene, 2,4-diethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)
MF C17 H18 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 2 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 524714-70-3 REGISTRY
ED Entered STN: 03 Jun 2003
CN Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-2-[[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)
MF C18 H20 N2 O5 S2
SR Chemical Library
Supplier: Ambinter
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 353484-05-6 REGISTRY
ED Entered STN: 29 Aug 2001
CN Acetic acid, [[4-cyano-5,6,7,8-tetrahydro-1-(1-piperidinyl)-3-isoquinolinyl]thio]- (9CI) (CA INDEX NAME)
MF C17 H21 N3 O2 S
SR Chemical Library
Supplier: Interbioscreen Ltd.
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 306764-68-1 REGISTRY
ED Entered STN: 05 Dec 2000
CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)
MF C18 H19 Cl N2 O5 S2
SR Chemical Library
Supplier: AsInEx
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 127464-60-2 REGISTRY
ED Entered STN: 01 Jun 1990
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Animal growth regulator, VEGF
CN Animal growth regulators, glioma-derived vascular endothelial growth factors
CN Animal growth regulators, VEGF
CN Animal growth regulators, VEGF (vascular endothelial growth factor)
CN Cytokines, vascular permeability factor
CN Folliculo-stellate-derived growth factors
CN FSdGF pituitary hormones
CN Glioma-derived vascular endothelial growth factors
CN Pituitary hormones, folliculo-stellate-derived growth factors
CN Vascular permeability factor

CN Vasculotropin
CN VEGF
MF Unspecified
CI MAN
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, DDFU, DRUGU, EMBASE, IPA, PHAR, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16292 REFERENCES IN FILE CA (1907 TO DATE)
195 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
16408 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 76293-13-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN 9H-Thioxanthen-9-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2,4-Dimethylthioxanone
CN 2,4-Dimethylthioxanthen-9-one
CN 2,4-Dimethylthioxanthone
CN Kayacure RTX
CN RTX
DR 104709-02-6
MF C15 H12 O S
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMLIST, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

76 REFERENCES IN FILE CA (1907 TO DATE)
76 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 66085-59-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (±)-Nimodipine
CN Admon
CN BAY-e 9736
CN Nimodipine
CN Nimodipine AP

CN Nimotop
CN Periplum
DR 155861-30-6, 82219-46-3
MF C21 H26 N2 O7
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIUDB, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2296 REFERENCES IN FILE CA (1907 TO DATE)
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2299 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 8-17

L13 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 40622-01-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2,3-Bis(4-methoxyphenyl)quinoxaline-6-carboxylic acid
CN 6-Carboxy-2,3-bis(p-methoxyphenyl)quinoxaline
MF C23 H18 N2 O4
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 21829-28-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, diethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-, diethyl ester (7CI, 8CI)
OTHER NAMES:
CN 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid diethyl ester
CN Diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
CN Metanifedipine
CN NSC 136464
MF C19 H22 N2 O6
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

151 REFERENCES IN FILE CA (1907 TO DATE)
151 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 7741-53-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 9H-Thioxanthene, 2,4-dimethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thioxanthene, 2,4-dimethyl-, 10,10-dioxide (7CI, 8CI)

OTHER NAMES:
CN 2,4-Dimethylthioxanthene 10,10-dioxide
MF C15 H14 O2 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL
    (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 7722-84-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Hydrogen peroxide (H2O2) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydrogen peroxide (8CI)
OTHER NAMES:
CN Adeka Super EL
CN Albone
CN Albone 35
CN Albone DS
CN Anti-Keim 50
CN Asepticper
CN Baquashock
CN CIX
CN Clarigel Gold
CN Crestal Whitestrips
CN Crystacide
CN Dentasept
CN Deslime LP
CN Hioxyl
CN Hipox
CN Hybrite
CN Hydrogen dioxide
CN Inhibine
CN Lase Peroxide
CN Lensan A
CN Magic Bleaching
CN Metrokur
CN Microcyn 60
CN Mirasept
CN Nite White Excel 2
CN NSC 19892
CN Odosat D
CN Opalescence Xtra
CN OxiDate
CN Oxigenal
CN Oxydol
CN Oxyfull

CN Oxysept
CN Oxysept I
CN Pegasyl
CN Perhydrol
CN Perone
CN Peroxaan
CN Peroxclean
CN Quasar Brite
CN Select Bleach
CN Superoxol
CN T-Stuff
CN Whiteness HP
CN Whitespeed
CN Xtra White
DR 8007-30-5, 66554-50-5, 37355-84-3, 218625-72-0
MF H2 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, PS, RTECS*, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

HO—OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

98203 REFERENCES IN FILE CA (1907 TO DATE)
818 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
98522 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 7440-70-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN Calcium (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Atomic calcium
CN Blood-coagulation factor IV
CN Calcium atom
CN Calcium element
CN Praval
DR 8047-59-4
MF Ca
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Ca

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

380239 REFERENCES IN FILE CA (1907 TO DATE)
8921 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
380912 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 7440-66-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-13L
CN AN 325
CN Asarco L 15
CN Blue powder
CN Ecka 4
CN F 1000
CN F 1000 (metal)
CN F 1500T
CN F 2000
CN F 2000 (metal)
CN LS 2
CN LS 2 (element)
CN LS 30
CN LS 4
CN LS 5
CN LS 5 (metal)
CN MCS
CN MCS (metal)
CN MS 10
CN MS 10 (metal)
CN NC-Zinc
CN PTzR 4
CN Rheinzink
CN RZN11-1
CN SK 2
CN SK 2 (metal)
CN Stapa TE Zinc AT
CN Tc 8
CN Tc 8 (metal)
CN UF
CN UF (metal)
CN VM 4P16
CN Z 620
CN Zinc Dust 3
DR 12793-53-2, 195161-85-4, 199281-21-5, 298688-49-0
MF Zn
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Zn

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

296943 REFERENCES IN FILE CA (1907 TO DATE)
15118 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
297480 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 1226-42-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN Ethanedione, bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Anisil (6CI)
CN p-Anisil (7CI, 8CI)
OTHER NAMES:
CN 1,2-Bis(4-methoxyphenyl)-1,2-ethanedione
CN 4,4'-Dimethoxybenzil
CN Bis(4-methoxyphenyl)ethanedione
CN Bis(p-methoxyphenyl)ethanedione
CN Di-p-anisylethanedione
CN NSC 19218
CN NSC 602910
CN p,p'-Dimethoxybenzil
MF C16 H14 O4
CI COM
LC STN Files: AQUIRE, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

602 REFERENCES IN FILE CA (1907 TO DATE)
602 REFERENCES IN FILE CAPLUS (1907 TO DATE)
18 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 619-05-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzoic acid, 3,4-diamino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3,4-Diaminobenzoic acid
CN 4-Carboxy-1,2-diaminobenzene
CN 4-Carboxy-o-phenylenediamine
MF C7 H8 N2 O2
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, GMELIN*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

458 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
458 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 108-38-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzene, 1,3-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN m-Xylene (8CI)
OTHER NAMES:
CN 1,3-Dimethylbenzene
CN 1,3-Xylene
CN m-Dimethylbenzene
CN m-Methyltoluene
CN m-xylol
CN NSC 61769
MF C8 H10
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17165 REFERENCES IN FILE CA (1907 TO DATE)
131 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
17193 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L13 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2006 ACS on STN
RN 60-92-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Adenosine, cyclic 3',5'-(hydrogen phosphate) (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4H-Furo[3,2-d]-1,3,2-dioxaphosphorin, adenosine deriv.

CN *Adenosine 3',5'-cyclic phosphate (6CI)
OTHER NAMES:
CN 1: PN: US20040005997 TABLE: 1 claimed sequence
CN 3',5'-AMP
CN 45: PN: US20030109453 SEQID: 44 claimed sequence
CN Adenosine 3',5'-cyclophosphate
CN Adenosine 3',5'-monophosphate
CN Adenosine 3',5'-phosphate
CN Adenosine cyclic 3',5'-monophosphate
CN Adenosine cyclic monophosphate
CN cAMP
CN Cyclic 3',5'-adenylic acid
CN Cyclic 3',5'-AMP
CN Cyclic adenosine 3',5'-monophosphate
CN Cyclic adenosine 3',5'-phosphate
CN Cyclic AMP
CN NSC 143670
CN NSC 94017
FS STEREOSEARCH
DR 11002-78-1
MF C10 H12 N5 O6 P
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

60343 REFERENCES IN FILE CA (1907 TO DATE)
347 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
60424 REFERENCES IN FILE CAPLUS (1907 TO DATE)
108 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>

C:\Program Files\Stnexp\Queries\egd7.str





chain nodes :
11 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
3-17 4-19 8-11 14-25 22-24
ring bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17 18-19
18-23 19-20 20-21 21-22 22-23
exact bonds :
3-17 4-19 8-11 14-25 22-24
normalized bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17 18-19
18-23 19-20 20-21 21-22 22-23

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
24:CLASS 25:CLASS

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS  4  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS  5  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS  6  SEP 11   CA/CAplus enhanced with more pre-1907 records
 NEWS  7  SEP 21   CA/CAplus fields enhanced with simultaneous left and right
                   truncation
 NEWS  8  SEP 25   CA(SM)/CAplus(SM) display of CA Lexicon enhanced
 NEWS  9  SEP 25   CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 10  SEP 25   CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
 NEWS 11  SEP 28   CEABA-VTB classification code fields reloaded with new
                   classification scheme
 NEWS 12  OCT 19   LOGOFF HOLD duration extended to 120 minutes
 NEWS 13  OCT 19   E-mail format enhanced
 NEWS 14  OCT 23   Option to turn off MARPAT highlighting enhancements available
 NEWS 15  OCT 23   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases
 NEWS 16  OCT 23   The Derwent World Patents Index suite of databases on STN
                   has been enhanced and reloaded
 NEWS 17  OCT 30   CHEMLIST enhanced with new search and display field
 NEWS 18  NOV 03   JAPIO enhanced with IPC 8 features and functionality
 NEWS 19  NOV 10   CA/CAplus F-Term thesaurus enhanced
 NEWS 20  NOV 10   STN Express with Discover! free maintenance release Version
                   8.01c now available
 NEWS 21  NOV 13   CA/CAplus pre-1967 chemical substance index entries enhanced
                   with preparation role
 NEWS 22  NOV 20   CAS Registry Number crossover limit increased to 300,000 in
                   additional databases
 NEWS 23  NOV 20   CA/CAplus to MARPAT accession number crossover limit increased
                   to 50,000
 NEWS 24  NOV 20   CA/CAplus patent kind codes will be updated
 NEWS 25  DEC 01   CAS REGISTRY updated with new ambiguity codes
 NEWS 26  DEC 11   CAS REGISTRY chemical nomenclature enhanced
 NEWS 27  DEC 14   WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 28  DEC 14   GBFULL and FRFULL enhanced with IPC 8 features and
                   functionality

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
```

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:00:01 ON 15 DEC 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:00:40 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 DEC 2006 HIGHEST RN 915690-78-7
DICTIONARY FILE UPDATES: 14 DEC 2006 HIGHEST RN 915690-78-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\egd7.str

L1 STRUCTURE UPLOADED

=> s sss l1 full
FULL SEARCH INITIATED 10:01:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 96 TO ITERATE

100.0% PROCESSED 96 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

L2 5 SEA SSS FUL L1

=> file caplus biosis embase uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.70	168.91

FILE 'CAPLUS' ENTERED AT 10:03:22 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'BIOSIS' ENTERED AT 10:03:22 ON 15 DEC 2006

FILE 'EMBASE' ENTERED AT 10:03:22 ON 15 DEC 2006

FILE 'USPATFULL' ENTERED AT 10:03:22 ON 15 DEC 2006

=> s l2
L3 14 L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 9 DUP REM L3 (5 DUPLICATES REMOVED)

=> d ibib abs hitstr 1-9

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:1242755 CAPLUS
DOCUMENT NUMBER: 143:472565
TITLE: Methods of treating conditions associated with an Edg-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 352,579.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261298	A1	20051124	US 2003-390428	20030314
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2002-350446P	P 20020118
	WO 2003-US1881	A1 20030121
	US 2003-352579	B2 20030127
	US 2002-350445P	P 20020118
	US 2002-350447P	P 20020118
	US 2002-350448P	P 20020118

OTHER SOURCE(S): MARPAT 143:472565
AB In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a subject. A therapeutically

effective amount of a modulator of the Edg-7 receptor is administered to the subject.

IT 40622-01-3P, 2,3-Bis(4-Methoxyphenyl)quinoxaline-6-carboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:703124 CAPLUS

DOCUMENT NUMBER: 141:218944

TITLE: Treating conditions associated with an Edg-7 receptor

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167165	A1	20040826	US 2004-760062		20040116
PRIORITY APPLN. INFO.:			US 2003-440336P	P	20030116

OTHER SOURCE(S): MARPAT 141:218944

GI



I



II

AB The invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biol. activity. The invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a subject. A therapeutically effective amount of the Edg-7 receptor

modulator with formula I (where R1,R2 R3 R4 and R7 = -H,-halo,-CN, -NO2 etc. independently) or with formula II (where R1, R2, R3, R4 and R7 = -H,-halo, -NO2 -CN, etc.) or a pharmaceutically available solvate or hydrate therof is administered to the subject.

IT 40622-01-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treating conditions associated with an Edg-7 receptor)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2003:648269 CAPLUS

DOCUMENT NUMBER: 139:180519

TITLE: Quinoxaline-containing hyperbranched poly(benzoxazoles) rights of the government

INVENTOR(S): Tan, Loon-Seng; Baek, Jong-Beom

PATENT ASSIGNEE(S): United States Dept. of the Air Force, USA

SOURCE: U.S., 5 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6608171	B1	20030819	US 2002-192044	20020710

PRIORITY APPLN. INFO.: US 2002-192044 20020710

GI



I

AB A hyperbranched polymer having repeating units I (Q = O, S or NH) shows excellent processability and flexibility in engineering. The polymer is end-capped with an end-capper such as 2,3-diphenyl-6-carboxyquinoxaline

and 4-sulfobenzoic acid.

IT 40622-01-3P, 2,3-Bis(4-methoxyphenyl)quinoxaline-6-carboxylic Acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(manufacture of quinoxaline-containing hyperbranched poly(benzoxazoles))

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:312683 CAPLUS

DOCUMENT NUMBER: 138:321752

TITLE: Quinoxaline-containing AB2 monomers for hyperbranched aromatic polyamides

INVENTOR(S): Baek, Jong-Beom; Tan, Loon-sSng

PATENT ASSIGNEE(S): United States Dept. of the Air Force, USA

SOURCE: U.S., 5 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6552195	B1	20030422	US 2002-83963	20020227

PRIORITY APPLN. INFO.: US 2002-83963 20020227

GI



I

AB Polymerization of AB2 monomers of I type (Q = NH2, 4-aminophenoxy) results in hyperbranched aromatic polyamides. Two such monomers were prepared including 2,3-bis(4-aminophenyl)quinoxaline-6-carboxylic acid and 2,3-bis(4-aminophenyloxyphenyl)quinoxaline-6-carboxylic acid.

IT 40622-01-3P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(manufacture of quinoxaline-containing AB2 monomers for hyperbranched aromatic polyamides)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2003:255128 CAPLUS

DOCUMENT NUMBER: 138:272113

TITLE: Quinoxaline derivatives as AB2 monomers

INVENTOR(S): Tan, Loon-Seng; Baek, Jong-Beom

PATENT ASSIGNEE(S): The United States of America as Represented by the Secretary of the Air Force, USA

SOURCE: U.S., 5 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6541633	B1	20030401	US 2002-192040	20020710

PRIORITY APPLN. INFO.: US 2002-192040 20020710

GI



AB AB2 monomers I (Z = OH, SH, or NH2HCl) are useful for the preparation of hyperbranched polymers.

IT 40622-01-3P, 2,3-Bis(4-methoxyphenyl)quinoxaline-6-carboxylic acid
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(monomer precursor; quinoxaline derivs. as AB2 monomers for hyperbranched polymers)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS

DOCUMENT NUMBER: 139:143997

TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003062392	A2	20030731	WO 2003-US1881		20030121
WO 2003062392	A3	20050120			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2473740	AA	20030731	CA 2003-2473740		20030121
AU 2003214873	A1	20030902	AU 2003-214873		20030121
EP 1513522	A2	20050316	EP 2003-710713		20030121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005519915	T2	20050707	JP 2003-562260		20030121
US 2005261298	A1	20051124	US 2003-390428		20030314
PRIORITY APPLN. INFO.:			US 2002-350445P	P	20020118
			US 2002-350446P	P	20020118
			US 2002-350447P	P	20020118
			US 2002-350448P	P	20020118
			WO 2003-US1881	W	20030121

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT 40622-01-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:382305 CAPLUS

DOCUMENT NUMBER: 139:85736

TITLE: Room-temperature free-radical-induced polymerization of 1,1'-(methylenedi-1,4-phenylene)bismaleimide via a novel diphenylquinoxaline-containing hyperbranched aromatic polyamide

AUTHOR(S): Baek, Jong-Beom; Ferguson, John B.; Tan, Loon-Seng

CORPORATE SOURCE: Research Institute, University of Dayton, Dayton, OH, 45469, USA

SOURCE: Macromolecules (2003), 36(12), 4385-4396
CODEN: MAMOBX; ISSN: 0024-9297

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Two new diphenylquinoxaline-containing AB2 monomers, i.e., 2,3-bis(4-aminophenyl)quinoxaline-6-carboxylic acid (I), and 2,3-bis[4-(4-aminophenoxy)phenyl]quinoxaline-6-carboxylic acid (II) were prepared and polymerized via the Yamazaki reaction to form hyperbranched aromatic polyamides with -NH2 as the reactive chain-end groups. Although these AB2 monomers and their resp. hyperbranched polymers are structurally similar except for the presence of a p-phenyloxy spacer between the quinoxaline and p-aminophenyl segments in II and its polymer, the phys. and chemical properties of both monomers and hyperbranched polymers are distinctly different. It is believed that the tautomerism in I and its polymer is

likely the basis for these differences. Since the II polymer was only marginally soluble in polar aprotic solvents in which the I polymer readily dissolved, a known, soluble hyperbranched polyamide was prepared from 3,5-bis(4-aminophenyloxy)benzoic acid (III) for comparison purposes in a subsequent blends study. The curing behaviors and thermal properties of the hyperbranched I and III polyamides blended in 0.75-3.75 weight % with a common bismaleimide, i.e., 1,1'-(methylenedi-4,1-phenylene)bismaleimide (BMI), resin were studied with differential scanning calorimetry (DSC) and Fourier-transform IR (FTIR) spectroscopy. Whereas the DSC results indicated that the III polymer reacted normally with BMI in a Michael-addition fashion, followed by homopolymn. of the excess BMI, the I polymer appeared to be able to initiate free radical polymerization of BMI at room temperature after co-dissoln. with BMI in N-methyl-2-pyrrolidinone. The DSC results of the BMI/I polymer blends indicated that, at ≥1.5 weight % of I polymer, no exotherm attributable to the thermal curing of BMI was detected. ESR expts. confirmed that the paramagnetic species present in the I polymer were more reactive toward BMI in solution at room temperature than the radical detected in the III polymer. This unique property of the I polymer to initiate room-temperature radical polymerization of BMI makes it important as a prototype for the development of low-temperature, thermally curable thermosetting resin systems for high-temperature applications.

IT 40622-01-3P, 2,3-Bis(4-methoxyphenyl)quinoxaline-6-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; in preparation of monomers for synthesis of diphenylquinoxaline-containing hyperbranched aromatic polyamide for free-radical-induced polymerization of 1,1'-(methylenedi-1,4-phenylene)bismaleimide)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:438427 CAPLUS

DOCUMENT NUMBER: 101:38427

TITLE: Substituted 5- and 6-quinoxalinecarboxylic acids and their tuberculostatic activity

AUTHOR(S): Roubinek, Frantisek; Bydzovsky, Viktor; Budesinsky, Zdenek

CORPORATE SOURCE: Res. Inst. Pharm. Biochem., Prague, 130 00/3, Czech.

SOURCE: Collection of Czechoslovak Chemical Communications (1984), 49(1), 285-94
CODEN: CCCCAK; ISSN: 0366-547X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 101:38427
GI



AB Seventy-four title compds. I and II [R, R1 = alkyl, (un)substituted Ph, 2-furyl; RR1 = (CH2)n (n = 4, 5); R2 = H, HO] were prepared by condensation of RCOCOR1 with its corresponding diaminobenzoic acid. Some compds. exhibited in vitro tuberculostatic activity but failed in vivo.

IT 40622-01-3P 90833-65-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and tuberculostatic activity of)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-65-1 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT 90833-66-2P 90833-67-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 90833-66-2 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-67-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(3,4-dimethoxyphenyl)-7-hydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:65232 CAPLUS
DOCUMENT NUMBER: 78:65232
TITLE: Light-sensitive copying compositions
INVENTOR(S): Bauer, Sigrid; Sikora, Helga; Frass, Werner
PATENT ASSIGNEE(S): Kalle A.-G.
SOURCE: Ger. Offen., 34 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2064380	A	19720720	DE 1970-2064380	19701230
DE 2064380	B2	19800430		
DE 2064380	C3	19810122		
NL 7117474	A	19720704	NL 1971-17474	19711220
NL 169372	B	19820201		
NL 169372	C	19820701		
AU 7137387	A1	19730628	AU 1971-37387	19711224
CA 960902	A1	19750114	CA 1971-131111	19711224
AT 321713	B	19750410	AT 1971-11143	19711227
CH 567283	A	19750930	CH 1971-18968	19711227
BE 777423	A1	19720628	BE 1971-112305	19711228
ZA 7108622	A	19720927	ZA 1971-8622	19711228
IT 945669	A	19730510	IT 1971-55026	19711228
JP 55025410	B4	19800705	JP 1972-3924	19711228
ES 398454	A1	19740816	ES 1971-398454	19711229

GB 1381119	A	19750122	GB 1971-60420	19711229
SE 373440	B	19750203	SE 1971-16800	19711229
FR 2121126	A5	19720818	FR 1971-47492	19711230
PRIORITY APPLN. INFO.:			DE 1970-2064380 A	19701230

AB A light-sensitive copying composition is prepared that contains a polymer and a light-sensitive N-compound The N-compound contains ≥1 6-membered N-heterocyclic nucleus (pyridine, pyrazine, or dihydropyrazine) and ≥1 benzene nucleus as a substituent or fused to the heterocyclic nucleus. Further substituent can be present which do not have to be light-sensitive. The high-mol. N-compound may contain a multitude of light-sensitive residues. The copying material is coated on a support and has on its free side a coating film that is slightly permeable to O. The polymer may contain carbonic acid, phosphonic acid, sulfonic acid, or N-arylsulfonylurethane groups. The concentration of the light-sensitive compound is 0.5-30 weight parts per 100 weight parts of polymer.

IT 40622-01-3
RL: USES (Uses)
(light-sensitive compns. containing, for photoduplication)

RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:513625 CAPLUS
DOCUMENT NUMBER: 127:190650
TITLE: Preparation of dihydropyridines, pyridines, benzopyranones, and triazoloquinazolines for use as adenosine receptor antagonists
INVENTOR(S): Jacobson, Kenneth A.; Jiang, Ji-Long; Kim, Yong-Chul; Karton, Yishai; Van Rhee, Albert M.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727177	A2	19970731	WO 1997-US1252	19970129
WO 9727177	A3	19971113		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2244774	A1	19970731	CA 1997-2244774	19970129
CA 2244774	C	20061017		
AU 9722466	A	19970820	AU 1997-22466	19970129
AU 709190	B2	19990826		
EP 885192	A1	19981223	EP 1997-905627	19970129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000516910	T	20001219	JP 1997-527065	19970129
US 6066642	A	20000523	US 1998-117598	19981207
AU 9957171	A1	20000217	AU 1999-57171	19991101
AU 755525	B2	20021212		

PRIORITY APPLN. INFO.:	US 1996-10737P	P	19960129
	US 1996-21191P	P	19960703
	WO 1997-US1252	W	19970129

OTHER SOURCE(S): MARPAT 127:190650
GI



I



II

AB Dihydropyridines I [R2 = alkyl, haloalkyl, phenyl; R3 = alkyl, alkoxycarbonyl, alkylthiocarbonyl, alkylaminocarbonyl, alkyloxy; R2R3 = ring with 2 - 4 methylene groups; R4 = alkyl, aryl, alkenyl, alkylamino, alkyloxy, alkynyl; R5 = alkyloxycarbonyl, aryl, alkylthio, hydroxy, alkylamino; R6 = Ph, naphthyl], benzopyranones II [R1 = R3 = H, hydroxy, alkyloxy, alkylcarbonyloxy; R2 = H, hydroxy, alkyloxy, alkylcarbonyloxy,

alkenyloxy; R4 = Ph, styryl, phenylbutadienyl, phenylacetylenyl, iminomethyl], as well as pyridines and triazoloquinazolines, were prepared for pharmaceutical uses which involve blocking adenosine receptors such as treatment of cancer, inflammation, and asthma. Thus, 3,5,7-trimethoxyflavone was prepared by methylation of galangin with di-Me sulfate and gave Ki values of 0.509 ± 0.049, 6.45 ± 1.48, and 1.21 ± 0.30 μM for A1, A2a, A3 receptors, resp., when tested for displacement of specific [3H]PIA binding in rat brain membranes.

IT 21829-28-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydropyridines, pyridines, benzopyranones, and triazoloquinazolines for use as adenosine receptor antagonists)

RN 21829-28-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, diethyl ester (9CI) (CA INDEX NAME)



=>

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:542495 CAPLUS
DOCUMENT NUMBER: 139:374461
TITLE: Antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells
AUTHOR(S): Yoshida, Junko; Ishibashi, Takaharu; Nishio, Matomo
CORPORATE SOURCE: Department of Pharmacology, Kanazawa Medical University, Uchinada, Ishikawa, 920-0293, Japan
SOURCE: European Journal of Pharmacology (2003), 472(1-2), 23-31
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of Ca2+ channel blockers on the proliferation of human epidermoid carcinoma A431 cells were investigated by microtiter tetrazolium (MTT) proliferation assay and bromodeoxyuridine (BrdU) incorporation assay. Dihydropyridine derivs., such as amlodipine, nicardipine, and nimodipine inhibited A431 cell growth and the incorporation of BrdU into cells with IC50 values of 20-30 μM, while verapamil, diltiazem and dihydropyridine nifedipine inhibited neither the cell growth nor BrdU incorporation at the same concentration Though extracellular Ca2+ is indispensable to the cell growth, an L-type Ca2+ channel agonist, 1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl) phenyl]pyridine-3-carboxylic acid Me ester (200 nM), did not affect the antiproliferative action of amlodipine. Thapsigargin, an inhibitor of Ca2+-ATPase of the endoplasmic reticulum, inhibited itself the growth of A431 cells and also showed a synergistic effect with the antiproliferative action of amlodipine. In the fluorimetric measurement of intracellular free Ca2+ concentration in fura-2 or fluo-3 loaded A431 cells, amlodipine blunted the thapsigargin- or cyclopiazonic acid-induced Ca2+ release from endoplasmic reticulum and the ensuing Ca2+ influx through Ca2+-permeable channels. The effect on the thapsigargin-induced Ca2+ responses could be reproduced by nicardipine and nimodipine but not by nifedipine or verapamil, lacking antiproliferative potency. These findings suggest that the intracellular Ca2+ control system responsible for thapsigargin- and cyclopiazonic acid-sensitive endoplasmic reticulum, but not L-type Ca2+ channels, may be modulated by amlodipine, which results in the inhibition of A431 cell growth.

IT 66085-59-4, Nimodipine
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells)

RN 66085-59-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:1047249 CAPLUS
TITLE: Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels
AUTHOR(S): Noel, Sabrina; Faveau, Christelle; Norez, Caroline; Rogier, Christian; Mettey, Yvette; Becq, Frederic
CORPORATE SOURCE: Institut de Physiologie et Biologie Cellulaires Centre National de la Recherche Scientifique (CNRS) Unite Mixte de Recherche 6187, Universite de Poitiers, Poitiers, Fr.
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2006), 319(1), 349-359
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The cystic fibrosis transmembrane conductance regulator (CFTR) represents the main Cl- channel in the apical membrane of epithelial cells for cAMP-dependent Cl- secretion. Here we report on the synthesis and screening of a small library of 6-phenylpyrrolo[2,3-b]pyrazines (named RP derivs.) evaluated as activators of wild-type CFTR, G551D-CFTR, and F508del-CFTR Cl- channels. Iodide efflux and whole-cell patch-clamp recordings anal. identified RP107 [7-n-butyl-6-(4-hydroxyphenyl)[5H]-pyrrolo[2,3-b]pyrazine] as a submicromolar activator of wild-type (WT)-CFTR [human airway epithelial Calu-3 and WT-CFTR-Chinese hamster ovary (CHO) cells], G551D-CFTR (G551D-CFTR-CHO cells), and F508del-CFTR (in temperature-corrected human airway epithelial F508del/F508del CF15 cells). The structural analog RP108 [7-n-butyl-6-(4-chlorophenyl)[5H]pyrrolo[2,3-b]pyrazine], contrary to RP107, was a less potent activator only at micromolar concns. RP107 and RP108 did not have any effect on the cellular cAMP level. Activation was potentiated by low concentration of forskolin and inhibited by glibenclamide and CFTRinh-172 [3-[(3-trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone]but not by calixarene or DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid). Finally, we found significant stimulation of short circuit current (Isc) by RP107 (EC50 = 89 nM) and RP108 (EC50 = 103 μM) on colon of Cftr+/+ but not of Cftr-/- mice mounted in Ussing chamber. Stimulation of Isc was inhibited by glibenclamide but not affected by DIDS. These results show that RP107 stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Our preliminary structure-activity relationship study identified 4-hydroxyphenyl and 7-Bu as determinants required for activation of CFTR. The potency of these agents indicates that compds. in this class may be of therapeutic benefit in CFTR-related diseases, including cystic fibrosis.
IT 913748-29-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrrolopyrazines as submicromolar activators of cystic fibrosis transmembrane conductance regulator chloride channels)
RN 913748-29-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 123 USPATFULL on STN
ACCESSION NUMBER: 2005:31687 USPATFULL
TITLE: 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors
INVENTOR(S): Linden, Joel, Charlottesville, VA, UNITED STATES
MacDonald, Timothy L., Charlottesville, VA, UNITED STATES
Murphree, Lauren, Charlottesville, VA, UNITED STATES
Chordia, Mahendra D., Charlottesville, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005027125	A1	20050203	
APPLICATION INFO.:	US 2004-499291	A1	20040618	(10)
	WO 2003-US1396		20030116	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349191P	20020116 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Charles W Calkins, Kilpatrick Stockton, 1001 W Fourth Street, Winston Salem, NC, 27101
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 1851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to a class of 2-aminothiazole derivatives which have recently been identified as allosteric enhancers of the A1? adenosine receptor. These compounds, and therapeutic compositions containing them, are useful for treating conditions in which activation of the A1? adenosine receptor would be beneficial, for example, those conditions in which stimulation of angiogenesis would improve blood flow to ischemic tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 896132-56-2P 896132-61-9P 896132-62-0P
896132-66-4P
(preparation of 2-aminothiazole allosteric enhancers of A1 adenosine receptors)
RN 896132-56-2 USPATFULL
CN 8H-Indeno[1,2-d]thiazol-2-amine, 6-methoxy-7-(4-methoxyphenyl)-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 896132-61-9 USPATFULL
CN Naphtho[1,2-d]thiazol-2-amine, 4,5-dihydro-6-methoxy-7-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 896132-62-0 USPATFULL
CN Naphtho[1,2-d]thiazol-2-amine, 4,5-dihydro-7-methoxy-6-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 896132-66-4 USPATFULL
CN Acetamide, N-[2-amino-5-(4-methoxyphenyl)-8H-indeno[1,2-d]thiazol-6-yl]-,
monohydriodide (9CI) (CA INDEX NAME)



● HI

L9 ANSWER 17 OF 123 USPATFULL on STN
ACCESSION NUMBER: 2006:222350 USPATFULL
TITLE: Inhibitors of E1 activating enzymes
INVENTOR(S): Critchley, Stephen, Braintree, MA, UNITED STATES
Gant, Thomas G., Carlsbad, CA, UNITED STATES
Langston, Steven P., North Andover, MA, UNITED STATES
Olhava, Edward J., Brookline, MA, UNITED STATES
Peluso, Stephane, Somerville, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006189636	A1	20060824	
APPLICATION INFO.:	US 2006-346469	A1	20060202	(11)

NUMBER DATE

PRIORITY INFORMATION:	US 2005-650433P 20050204 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139, US
NUMBER OF CLAIMS:	30
EXEMPLARY CLAIM:	1
LINE COUNT:	7393

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 905580-85-0P 905580-87-2P 905580-88-3P
905580-89-4P
(preparation of nucleoside derivs. as inhibitors of E1 activating enzymes)

RN 905580-85-0 USPATFULL

CN Oxireno[4,5]cyclopenta[1,2-d][1,3]dioxin, hexahydro-3-(4-methoxyphenyl)-, (1aS,1bR,5aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905580-87-2 USPATFULL

CN Cyclopenta-1,3-dioxin-7-ol, 6-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]hexahydro-2-(4-methoxyphenyl)-, (4aS,6R,7S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905580-88-3 USPATFULL
CN Carbonothioic acid, O-[(4aS,6R,7S,7aR)-6-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]hexahydro-2-(4-methoxyphenyl)cyclopenta-1,3-dioxin-7-yl] O-phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905580-89-4 USPATFULL
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(1S)-2,3-dihydro-1H-inden-1-yl]-7-[(4aS,6R,7aS)-hexahydro-2-(4-methoxyphenyl)cyclopenta-1,3-dioxin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 18 OF 123 USPATFULL on STN
ACCESSION NUMBER: 2006:111747 USPATFULL
TITLE: Heterocyclic compounds and thrombopoietin receptor activators
INVENTOR(S): Owada, Shingo, Funabashi-shi, JAPAN
Iwamoto, Shunsuke, Funabashi-shi, JAPAN
Yanagihara, Kazufumi, Funabashi-shi, JAPAN
Miyaji, Katsuaki, Funabashi-shi, JAPAN
Nakamura, Takanori, Minami-saitama-gun, JAPAN
Ishiwata, Norihisa, Minami-saitama-gun, JAPAN
Hirokawa, Yutaka, Funabashi-shi, JAPAN
PATENT ASSIGNEE(S): Nissan Chemical Industries Limited, Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006094694	A1	20060504
APPLICATION INFO.:	US 2005-294609	A1	20051206 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2004-JP8165, filed on 4 Jun 2004, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-161987	20030606
	JP 2003-330627	20030922
	JP 2003-404635	20031203
	JP 2004-94931	20040329

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
NUMBER OF CLAIMS: 118
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 32462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound represented by the formula (1): ##STR1## wherein A is a nitrogen atom or CR.sup.4, B is an oxygen atom, a sulfur atom or NR.sup.9 (provided that when A is a nitrogen atom, B is not NH), R.sup.1 is a C.sub.2-14 aryl group, L.sup.1 is a bond, CR.sup.10R.sup.11, an oxygen atom, a sulfur atom or NR.sup.12, X is OR.sup.13 SR.sup.13 or NR.sup.14NR.sup.15, R.sup.2 is a hydrogen atom, a formyl group, a C.sub.1-10 alkyl group or the like, L.sup.2 is a bond or the like, L.sup.3 is a bond, CR.sup.17R.sup.18, an oxygen atom, a sulfur atom or NR.sup.19, L.sup.4 is a bond, CR.sup.20R.sup.21, an oxygen atom, a sulfur atom or NR.sup.22, Y is an oxygen atom, a sulfur atom or NR.sup.23, and R.sup.3 is a C.sub.2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 885602-03-9P 885602-06-2P 885602-16-4P
885602-63-1P 885602-64-2P 885602-65-3P
885602-66-4P 885602-90-4P 885602-92-6P
885602-99-3P
(preparation of 3-alkylidenehydrazino-substituted heteroarenes as thrombopoietin receptor activators)
RN 885602-03-9 USPATFULL
CN Benzoic acid, 4-[[[[1-[4-hydroxy-5-(4-methoxyphenyl)-3-thienyl]ethylidene]hydrazino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 885602-06-2 USPATFULL
CN Benzoic acid, 3-[[[[1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]ethylidene]hydrazino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 885602-16-4 USPATFULL
CN Hydrazinecarbothioamide, N-[4-(aminosulfonyl)phenyl]-2-[1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]ethylidene]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 885602-63-1 USPATFULL
CN 1,4-Benzenedicarboxylic acid, 2-nitro-, 4-[[1-[4-hydroxy-5-(4-methoxyphenyl)-3-thienyl]ethylidene]hydrazide] (9CI) (CA INDEX NAME)



RN 885602-64-2 USPATFULL
CN Benzoic acid, 2-chloro-4-[[[[1-[4-hydroxy-5-(4-methoxyphenyl)-3-thienyl]ethylidene]hydrazino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 885602-65-3 USPATFULL
CN 1,4-Benzenedicarboxylic acid, 2-nitro-, 4-[[1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]ethylidene]hydrazide] (9CI) (CA INDEX NAME)



RN 885602-66-4 USPATFULL
CN Benzoic acid, 2-chloro-4-[[[[1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]ethylidene]hydrazino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 885602-90-4 USPATFULL
CN 2-Thiophenecarboxylic acid, 5-(1H-tetrazol-5-yl)-, [1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]ethylidene]hydrazide (9CI) (CA INDEX NAME)



RN 885602-92-6 USPATFULL
CN 1,4-Benzenedicarboxylic acid, 2-hydroxy-, 1-[[1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]ethylidene]hydrazide] (9CI) (CA INDEX NAME)



RN 885602-99-3 USPATFULL
CN 1,4-Benzenedicarboxylic acid, 2-amino-, 1-[[1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]ethylidene]hydrazide] (9CI) (CA INDEX NAME)



IT 885603-12-3P 885603-13-4P 885603-24-7P
885603-26-9P
(preparation of 3-alkylidenehydrazino-substituted heteroarenes as thrombopoietin receptor activators)
RN 885603-12-3 USPATFULL
CN Ethanone, 1-[4-hydroxy-5-(4-methoxyphenyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 885603-13-4 USPATFULL
CN Ethanone, 1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 885603-24-7 USPATFULL
CN Ethanone, 1-[4-hydroxy-5-(4-methoxyphenyl)-3-thienyl]-, hydrazone (9CI) (CA INDEX NAME)



RN 885603-26-9 USPATFULL
CN Ethanone, 1-[4-hydroxy-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]-, hydrazone (9CI) (CA INDEX NAME)



L11 ANSWER 9 OF 56 USPATFULL on STN

ACCESSION NUMBER: 2006:111747 USPATFULL

TITLE: Heterocyclic compounds and thrombopoietin receptor activators

INVENTOR(S): Owada, Shingo, Funabashi-shi, JAPAN
Iwamoto, Shunsuke, Funabashi-shi, JAPAN
Yanagihara, Kazufumi, Funabashi-shi, JAPAN
Miyaji, Katsuaki, Funabashi-shi, JAPAN
Nakamura, Takanori, Minami-saitama-gun, JAPAN
Ishiwata, Norihisa, Minami-saitama-gun, JAPAN
Hirokawa, Yutaka, Funabashi-shi, JAPAN

PATENT ASSIGNEE(S): Nissan Chemical Industries Limited, Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006094694	A1	20060504
APPLICATION INFO.:	US 2005-294609	A1	20051206 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2004-JP8165, filed on 4 Jun 2004, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-161987	20030606
	JP 2003-330627	20030922
	JP 2003-404635	20031203
	JP 2004-94931	20040329

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US

NUMBER OF CLAIMS: 118

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 32462

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the formula (1): ##STR1## wherein A is a nitrogen atom or CR.sup.4, B is an oxygen atom, a sulfur atom or NR.sup.9 (provided that when A is a nitrogen atom, B is not NH), R.sup.1 is a C.sub.2-14 aryl group, L.sup.1 is a bond, CR.sup.10R.sup.11, an oxygen atom, a sulfur atom or NR.sup.12, X is OR.sup.13 SR.sup.13 or NR.sup.14NR.sup.15, R.sup.2 is a hydrogen atom, a formyl group, a C.sub.1-10 alkyl group or the like, L.sup.2 is a bond or the like, L.sup.3 is a bond, CR.sup.17R.sup.18, an oxygen atom, a sulfur atom or NR.sup.19, L.sup.4 is a bond, CR.sup.20R.sup.21, an oxygen atom, a sulfur atom or NR.sup.22, Y is an oxygen atom, a sulfur atom or NR.sup.23, and R.sup.3 is a C.sub.2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 55 OF 56 USPATFULL on STN

ACCESSION NUMBER:	2006:167047 USPATFULL
TITLE:	Site-specific labeling of affinity tags in fusion proteins
INVENTOR(S):	Gee, Kyle Richard, Springfield, OR, UNITED STATES Hart, Courtenay Rae, Eugene, OR, UNITED STATES Haugland, Richard, Eugene, OR, UNITED STATES Patton, Wayne Forrest, Newton, MA, UNITED STATES Whitney, Scott, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006141554	A1	20060629
APPLICATION INFO.:	US 2004-966536	A1	20041014 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-661451, filed on 12 Sep 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-410612P	20020912 (60)
	US 2003-458472P	20030328 (60)
	US 2003-511252P	20031014 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	KOREN ANDERSON, MOLECULAR PROBES, INC., 29851 WILLOW CREEK ROAD, EUGENE, OR, 97402-9132, US
NUMBER OF CLAIMS:	42
EXEMPLARY CLAIM:	2
NUMBER OF DRAWINGS:	6 Drawing Page(s)
LINE COUNT:	3936

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula A(B)n, wherein A is a fluorophore, B is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody. The present invention provides specific fluorescent compounds and methods used to detect and label fusion proteins that contain a poly-histidine affinity tag. These compounds have the general formula A(L)m(B)n wherein A is a fluorophore, L is a linker, B is an acetic acid binding domain, m is an integer from 1 to 4 and n is an integer from 1 to 6. The acetic acid groups interact directly with the positively charged histidine residues of the affinity tag to effectively label and detect a fusion protein containing such an affinity tag when present in an acidic or neutral environment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 1 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:438427 CAPLUS
DOCUMENT NUMBER: 101:38427
TITLE: Substituted 5- and 6-quinoxalinecarboxylic acids and their tuberculostatic activity
AUTHOR(S): Roubinek, Frantisek; Bydzovsky, Viktor; Budesinsky, Zdenek
CORPORATE SOURCE: Res. Inst. Pharm. Biochem., Prague, 130 00/3, Czech.
SOURCE: Collection of Czechoslovak Chemical Communications (1984), 49(1), 285-94
CODEN: CCCCAK; ISSN: 0366-547X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 101:38427
GI



I


II

AB Seventy-four title compds. I and II [R, R1 = alkyl, (un)substituted Ph, 2-furyl; RR1 = (CH2)n (n = 4, 5); R2 = H, HO] were prepared by condensation of RCOCOR1 with its corresponding diaminobenzoic acid. Some compds. exhibited in vitro tuberculostatic activity but failed in vivo.

IT 40622-01-3P 90833-49-1P 90833-50-4P
90833-53-7P 90833-54-8P 90833-56-0P
90833-64-0P 90833-65-1P 90833-69-5P
90833-70-8P 90833-71-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and tuberculostatic activity of)

RN 40622-01-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-49-1 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 90833-50-4 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 90833-53-7 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 90833-54-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-chlorophenyl)-7-hydroxy- (9CI) (CA INDEX NAME)



RN 90833-56-0 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-64-0 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-65-1 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-69-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(1,3-benzodioxol-5-yl)-7-hydroxy- (9CI) (CA INDEX NAME)



RN 90833-70-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 90833-71-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis[4-(dimethylamino)phenyl]-7-hydroxy- (9CI) (CA INDEX NAME)



IT 32387-96-5P 90833-46-8P 90833-47-9P
90833-48-0P 90833-51-5P 90833-52-6P
90833-55-9P 90833-57-1P 90833-58-2P
90833-59-3P 90833-60-6P 90833-61-7P
90833-62-8P 90833-63-9P 90833-66-2P
90833-67-3P 90833-68-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32387-96-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-diphenyl- (8CI, 9CI) (CA INDEX NAME)



RN 90833-46-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-diphenyl- (6CI, 9CI) (CA INDEX NAME)



RN 90833-47-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 90833-48-0 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 90833-51-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 90833-52-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(2-chlorophenyl)-7-hydroxy- (9CI) (CA INDEX NAME)



RN 90833-55-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-57-1 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-58-2 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-59-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-60-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-61-7 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-62-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 7-hydroxy-2,3-bis(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-63-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(3-methoxyphenyl)- (9CI) (CA INDEX NAME)





RN 90833-66-2 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90833-67-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(3,4-dimethoxyphenyl)-7-hydroxy- (9CI) (CA INDEX NAME)



RN 90833-68-4 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)



```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 14:07:41 ON 15 DEC 2006
FILE 'CAPLUS' ENTERED AT 14:07:41 ON 15 DEC 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  249.34     583.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -35.25     -35.25

=>
Uploading C:\Program Files\Stnexp\Queries\edg-7-3.str

L9      STRUCTURE UPLOADED

=> sss l9 full
SSS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s sss l9 full
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



FULL SEARCH INITIATED 14:08:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  4263489 TO ITERATE

 17.1% PROCESSED   728089 ITERATIONS                      175319 ANSWERS

 23.5% PROCESSED  1000000 ITERATIONS                      245431 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.29

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      4263489 TO  4263489
PROJECTED ANSWERS:         1043342 TO  1049442

L10      245431 SEA SSS FUL L9


L11      18103 L10

=>
```

```
Uploading C:\Program Files\Stnexp\Queries\egd-7-4.str

L12     STRUCTURE UPLOADED

=> s sss l12 full
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



FULL SEARCH INITIATED 14:13:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      365 TO ITERATE

100.0% PROCESSED      365 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

L13           0 SEA SSS FUL L12



L14          0 L13

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.46     921.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -35.25

FILE 'CAPLUS' ENTERED AT 14:13:18 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 14 Dec 2006  (20061214/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l11
L15      18103 L10

=> s l15 and (tumor or tumour or cancer or cancer? or neoplas? or carcinoma )
        392207 TUMOR
        153102 TUMORS
```

```
        440734 TUMOR
                 (TUMOR OR TUMORS)
          3074 TUMOUR
          1159 TUMOURS
          4171 TUMOUR
                 (TUMOUR OR TUMOURS)
        300139 CANCER
         43906 CANCERS
        311500 CANCER
                 (CANCER OR CANCERS)
        315231 CANCER?
        473976 NEOPLAS?
        152779 CARCINOMA
         31357 CARCINOMAS
           162 CARCINOMATA
        160511 CARCINOMA
                 (CARCINOMA OR CARCINOMAS OR CARCINOMATA)
L16       1404 L15 AND (TUMOR OR TUMOUR OR CANCER OR CANCER? OR NEOPLAS? OR
               CARCINOMA )

=> s l16 and (endothelial gene differentiation or edg)
        110079 ENDOTHELIAL
            12 ENDOTHELIALS
        110083 ENDOTHELIAL
                 (ENDOTHELIAL OR ENDOTHELIALS)
       1093422 GENE
        415894 GENES
       1159742 GENE
                 (GENE OR GENES)
        205899 DIFFERENTIATION
           757 DIFFERENTIATIONS
        206363 DIFFERENTIATION
                 (DIFFERENTIATION OR DIFFERENTIATIONS)
             0 ENDOTHELIAL GENE DIFFERENTIATION
                 (ENDOTHELIAL(W)GENE(W)DIFFERENTIATION)
           945 EDG
            25 EDGS
           960 EDG
                 (EDG OR EDGS)
L17          8 L16 AND (ENDOTHELIAL GENE DIFFERENTIATION OR EDG)

=> d ibib abs 1-8 hitstr

L17  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2006:605527  CAPLUS
DOCUMENT NUMBER:          145:62766
TITLE:                    Preparation of azetidinecarboxylic acid derivatives
                          and β-alanine derivatives having ability of
                          binding to sphingosine-1-phosphate (S1P) receptor
INVENTOR(S):              Habashita, Hiromu; Kurata, Haruto; Nakade, Shinji
PATENT ASSIGNEE(S):       Ono Pharmaceutical Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 201 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006064757         A1    20060622    WO 2005-JP22765         20051212
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
```

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2004-360539 A 20041213
JP 2005-125740 A 20050422
JP 2005-233790 A 20050811

OTHER SOURCE(S): MARPAT 145:62766

GI



I

AB Aminocarboxylic acid derivs. represented by general formula (I), salts thereof, N-oxides thereof, solvates thereof, or prodrugs of any of these [ring A = cyclic group; ring B = (un)substituted cyclic group; X = a bond, a spacer having 1-8 atom(s) in the principal chain wherein one of the spacer atoms optionally forms an (un)substituted ring together with a substituent of the ring B; Y = a bond, a spacer having 1-10 atom(s) in the principal chain wherein one of the spacer atoms optionally forms an (un)substituted ring together with a substituent of the ring B; Z = (un)protected acidic group; n = 0 or 1, provided that when n is 0, m represent 1 and when R1 is H or a substituent and n is 1, m represents 0 or an integer of 1-7; R1 = a substituent] are prepared These compds. have the ability to bind with an S1P receptor (especially EDG-1, EDG-6, and/or EDG-8) and are agonists of EDG -1, EDG-6, and/or EDG-8. They are useful as immunosuppressants and/or for a method for decreasing lymphocyte and thereby for the prevention and/or treatment of diseases related to EDG-1, EDG-6, and/or EDG-8 which include rejection reactions to transplantation, graft vs. host diseases, autoimmune diseases, allergic diseases, neurodegenerative diseases, etc. Thus, 4.33 mL Et3N, 4.71 g Me azetidine-3-carboxylate hydrochloride, and 9.88 g sodium triacetoxyborohydride were successively added to a solution of 5.04 g 6-[3-(4-fluorophenyl)propoxy]-1-methyl-3,4-dihydronaphthalene-2-carboxaldehyde in 50 mL THF and the resulting mixture was stirred at room temperature for 2.5 h to give, after workup and silica gel chromatog., 6.12 g Me 1-[[6-[3-(4-fluorophenyl)propoxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]-3-azetidinecarboxylate. In an EDG-1 agonist assay, 1-[[1-chloro-6-[(2-methoxy-4-propylbenzyl)oxy]-3,4-dihydro-2-naphthalenyl]methyl]-3-azetidinecarboxylic acid showed EC50 of 0.7 nmol/L for increasing the cellular Ca2+ ion concentration in CHO cells expressing EDG-1. A tablet and ampule formulation-containing 1-[[1-chloro-6-(3-cyclohexylpropoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid were prepared

IT 891858-63-2P, tert-Butyl 3-[3-[4-(3-phenylpropoxy)benzylidene]-1-piperidinyl]propanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azetidinecarboxylic acid derivs. and β-alanine derivs. having ability of binding to

sphingosine-1-phosphate (S1P) receptor)

RN 891858-63-2 CAPLUS

CN 1-Piperidinepropanoic acid, 3-[[4-(3-phenylpropoxy)phenyl]methylene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 891858-77-8P, Methyl 1-[[6-[3-(4-methoxyphenyl)propoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylate
891858-80-3P, Methyl 1-[(2E)-3-[4-[[(2S)-3-(4-chlorophenyl)-2-methylpropyl]oxy]phenyl]but-2-enyl]azetidine-3-carboxylate
891858-93-8P, 1-[[6-[3-(4-Methoxyphenyl)propoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid
891858-96-1P, 1-[(2E)-3-[4-[[(2S)-3-(4-Chlorophenyl)-2-methylpropyl]oxy]phenyl]but-2-enyl]azetidine-3-carboxylic acid
891858-97-2P, 1-[(2E)-3-[4-[3-(4-Chlorophenyl)propoxy]phenyl]but-2-enyl]azetidine-3-carboxylic acid 891859-20-4P,
1-[[6-[[4-Isopropoxy-2-(trifluoromethyl)benzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891859-29-3P,
1-[[6-[[4-Ethoxy-2-(trifluoromethyl)benzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891859-97-5P
891860-03-0P 891860-09-6P 891860-23-4P,
1-[[6-[(2,4-Dimethoxybenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-25-6P,
1-[[6-[[4-(Benzyloxy)-2-methoxybenzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-35-8P,
1-[[6-[(4-Isopropoxy-2-methoxybenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-45-0P,
1-[[6-[[2-Methoxy-4-[((1S)-1-methylpropyl)oxy]benzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid
891860-47-2P, 1-[[6-[[2-Methoxy-4-[((1R)-1-methylpropyl)oxy]benzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-53-0P,
1-[[1-Methyl-6-[[4-propoxy-2-(trifluoromethyl)benzyl]oxy]-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-55-2P,
1-[[6-[[4-Butoxy-2-(trifluoromethyl)benzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-61-0P,
1-[[6-[[4-Isobutoxy-2-(trifluoromethyl)benzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-75-6P,
1-[[6-[(2-Fluoro-4-isopropoxybenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-79-0P,
1-[[6-[(2-Cyano-4-isopropoxybenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-84-7P,
1-[[6-[[4-Isopropoxy-2-(methylsulfonyl)benzyl]oxy]-1-methyl-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-97-2P,
1-[[1-Chloro-6-[[4-ethoxy-2-(trifluoromethyl)benzyl]oxy]-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891860-98-3P,
1-[[1-Chloro-6-[[4-isopropoxy-2-(trifluoromethyl)benzyl]oxy]-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid 891861-19-1P,
1-[[1-Methyl-6-[[4-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)benzyl]oxy]-3,4-dihydro-2-naphthalenyl]methyl]azetidine-3-carboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azetidinecarboxylic acid derivs. and β-alanine derivs. having ability of binding to sphingosine-1-phosphate (S1P) receptor)

RN 891858-77-8 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[3-(4-methoxyphenyl)propoxy]-

1-methyl-2-naphthalenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 891858-80-3 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[(2E)-3-[4-[(2S)-3-(4-chlorophenyl)-2-methylpropoxy]phenyl]-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 891858-93-8 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[3-(4-methoxyphenyl)propoxy]-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891858-96-1 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[(2E)-3-[4-[(2S)-3-(4-chlorophenyl)-2-methylpropoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 891858-97-2 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[(2E)-3-[4-[3-(4-chlorophenyl)propoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 891859-20-4 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-1-methyl-6-[[4-(1-methylethoxy)-2-(trifluoromethyl)phenyl]methoxy]-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891859-29-3 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[6-[[4-ethoxy-2-(trifluoromethyl)phenyl]methoxy]-3,4-dihydro-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891859-97-5 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[(2Z)-3-chloro-3-[4-[(2S)-3-(4-fluorophenyl)-2-methylpropoxy]phenyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 891860-03-0 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[(2E)-3-[4-[(2S)-3-(4-chlorophenyl)-2-methylpropoxy]-2-methylphenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 891860-09-6 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[(2Z)-3-chloro-3-[4-[(2S)-3-(4-fluorophenyl)-2-methylpropoxy]-2-methylphenyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 891860-23-4 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[6-[(2,4-dimethoxyphenyl)methoxy]-3,4-dihydro-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-25-6 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[[2-methoxy-4-(phenylmethoxy)phenyl]methoxy]-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-35-8 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[[2-methoxy-4-(1-methylethoxy)phenyl]methoxy]-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-45-0 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[[2-methoxy-4-[(1S)-1-methylpropoxy]phenyl]methoxy]-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 891860-47-2 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[[2-methoxy-4-[(1R)-1-methylpropoxy]phenyl]methoxy]-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 891860-53-0 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-1-methyl-6-[[4-propoxy-2-(trifluoromethyl)phenyl]methoxy]-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-55-2 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[6-[[4-butoxy-2-(trifluoromethyl)phenyl]methoxy]-3,4-dihydro-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-61-0 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-1-methyl-6-[[4-(2-methylpropoxy)-2-(trifluoromethyl)phenyl]methoxy]-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-75-6 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[6-[[2-fluoro-4-(1-methylethoxy)phenyl]methoxy]-3,4-dihydro-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-79-0 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[6-[[2-cyano-4-(1-methylethoxy)phenyl]methoxy]-3,4-dihydro-1-methyl-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-84-7 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-1-methyl-6-[[4-(1-methylethoxy)-2-(methylsulfonyl)phenyl]methoxy]-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-97-2 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[1-chloro-6-[[4-ethoxy-2-(trifluoromethyl)phenyl]methoxy]-3,4-dihydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 891860-98-3 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[1-chloro-3,4-dihydro-6-[[4-(1-

methylethoxy)-2-(trifluoromethyl)phenyl]methoxy]-2-naphthalenyl]methyl]-
(9CI) (CA INDEX NAME)



RN 891861-19-1 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-1-methyl-6-[[4-(2,2,2-
trifluoroethoxy)-2-(trifluoromethyl)phenyl]methoxy]-2-naphthalenyl]methyl]-
(9CI) (CA INDEX NAME)



IT 891858-64-3, Triphenyl[4-(3-phenylpropoxy)benzyl]phosphonium
bromide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azetidinecarboxylic acid derivs. and β-alanine derivs.
having ability of binding to sphingosine-1-phosphate (S1P) receptor)
RN 891858-64-3 CAPLUS
CN Phosphonium, triphenyl[[4-(3-phenylpropoxy)phenyl]methyl]-, bromide (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:117144 CAPLUS
DOCUMENT NUMBER: 144:212779
TITLE: Preparation of triazole compounds having inhibitory activity for Edg-1(S1P) binding
INVENTOR(S): Ono, Naoya; Sato, Masakazu; Shiozawa, Fumiyasu; Yagi, Makoto; Yabuuchi, Tetsuya; Takayama, Tetsuo; Katakai, Hironori
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 154 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006013948	A1	20060209	WO 2005-JP14351	20050804

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2004-228394 A 20040804
JP 2005-121769 A 20050420

OTHER SOURCE(S): MARPAT 144:212779
GI



I



II

AB Title compds. I [A = S, O, SO, etc.; R1 = H, alkyl, alkenyl, etc.; R2 = alkyl, cycloalkyl, Ph, etc.; R3 = H, alkyl; R4 = H, alkyl, benzyl, etc.; R3 and R4 may combine to form saturated carbocycles; R5 = H, alkyl; Y = -SO2R6; R6 = alkyl, alkenyl, optionally substituted alkyl with Ph, halo, naphthyl, etc.] were prepared For example, S-allylation of 4-chloro-N-[1-(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)butyl]benzenesulfonamide, e.g., prepared from DL-norvaline in 4 steps, using allyl bromide afforded compound II. In S1P (sphingosine-1-phosphate)-Edg1 binding assays, compound II exhibited the inhibitory activity of 69%. Compds. I are claimed useful for the treatment of autoimmune diseases, asthma, etc.

IT 875568-58-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole compds. having inhibitory activity for Edg -1(S1P) binding)

RN 875568-58-4 CAPLUS

CN Benzenesulfonamide, 3,4-dichloro-N-[(1R)-1-(4-ethyl-5-propoxy-4H-1,2,4-triazol-3-yl)-2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:15820 CAPLUS

DOCUMENT NUMBER: 144:108361

TITLE: Preparation of heterocyclic compounds having sphingosine-1-phosphate (S1P) receptor binding potency

INVENTOR(S): Habashita, Hiromu; Nakade, Shinji

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006001463	A1	20060105	WO 2005-JP11872	20050622

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2004-185651 A 20040623

OTHER SOURCE(S): MARPAT 144:108361

GI



I

AB Heterocyclic compds. of the general formula (I), their salts, N-oxides, and solvates or prodrugs thereof [wherein ring A, D = a substituted or unsubstituted cyclic group; E, G = a bonding group or a spacer whose main chain has 1 to 8 atoms; L = H, a substituent; X = a substituted or unsubstituted amino or substituted or unsubstituted heterocycle containing at least one nitrogen atom; n is 0 to 3 with the proviso that when n is ≥2, multiple rings A may be identical with or different from each other] are prepared The compds. I, e.g. 1-((6-[(5-phenylpentyl)oxy]-2-naphthyl)methyl)-4-(2-pyridinyl)piperazine, have S1P receptor (especially EDG-1 and/or EDG-6) binding potency (no data) and are useful in the prevention and/or therapy for transplant rejection, autoimmune diseases (systemic lupus erythematosus, articular rheumatism, multiple sclerosis, psoriasis, inflammatory bowel diseases, autoimmune diabetes and/or collagen disease), allergic disorders (atopic dermatitis, pollinosis, and/or food allergy), asthma, multiple organ failure, postischemic reperfusion disorders, malignant tumors, pulmonary fibrosis. An tablet and an ampule formulation containing N-[[1-[[6-(3-phenylpropoxy)-2-naphthyl]methyl]azetidin-3-yl]carbonyl]benzenesulfonamide were prepared

IT 872709-26-7P 872709-48-3P, 3-Hydroxy-4-methyl-N-(2-(4-[(5-phenylpentyl)oxy]phenyl)ethyl)benzamide 872709-50-7P, 3-[(E)-(Hydroxyimino)methyl]-N-(2-(4-[(5-phenylpentyl)oxy]phenyl)ethyl)benzamide 872709-51-8P, 3,5-Bis(benzyloxy)-N-(2-(4-[(5-phenylpentyl)oxy]phenyl)ethyl)benzamide 872709-52-9P, 3,5-Dihydroxy-N-(2-(4-[(5-phenylpentyl)oxy]phenyl)ethyl)benzamide 872709-53-0P 872709-55-2P 872709-57-4P 872709-58-5P, 1-(3-(4-[(5-Phenylpentyl)oxy]phenyl)propanoyl)pyrrolidine 872709-59-6P, N-Phenyl-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-60-9P, (2S)-2-(Methoxymethyl)-1-(3-(4-[(5-phenylpentyl)oxy]phenyl)propanoyl)pyrrolidine 872709-61-0P, N-(3-Acetylphenyl)-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-62-1P 872709-63-2P 872709-64-3P, N-(2-Hydroxyethyl)-N-methyl-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-65-4P, 1-(3-[4-[(5-Phenylpentyl)oxy]phenyl]propanoyl)pyrrolidin-3-ol 872709-66-5P, 3-(4-[(5-Phenylpentyl)oxy]phenyl)-N-((tetrahydrofuran-2-yl)methyl)propanamide 872709-67-6P, 3-(4-[(5-Phenylpentyl)oxy]phenyl)-N-((pyridin-2-yl)methyl)propanamide 872709-68-7P, N-(2-Hydroxyethyl)-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-69-8P, N-[2-(2-Hydroxyethoxy)ethyl]-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-70-1P, N-(3-Hydroxy-4-methoxyphenyl)-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-71-2P, N-(3-Hydroxyphenyl)-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-72-3P, N-(3-Cyanophenyl)-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-73-4P, N-[3-(Aminosulfonyl)phenyl]-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-74-5P, N-(4-Chloro-3-cyanophenyl)-3-(4-[(5-phenylpentyl)oxy]phenyl)propanamide 872709-75-6P 872709-76-7P 872709-77-8P 872709-78-9P 872709-79-0P 872710-39-9P, 2-[N-(2,4-Dimethoxybenzyl)-N-((6-[(5-phenylpentyl)oxy]-2-naphthyl)methyl)amino]ethanol 872710-58-2P, 2-[N-(4-Methoxybenzyl)-N-((6-[(5-phenylpentyl)oxy]-2-naphthyl)methyl)amino]ethanol 872710-59-3P, 2-[N-[4-(Benzyloxy)benzyl]-N-((6-[(5-phenylpentyl)oxy]-2-naphthyl)methyl)amino]ethanol 872710-71-9P, 2-[N-[4-(Allyloxy)benzyl]-N-((6-[(5-phenylpentyl)oxy]-2-

naphthyl)methyl)amino]ethanol 872710-72-0P, 2-[N-[4-
(Octyloxy)benzyl]-N-((6-[(5-phenylpentyl)oxy]-2-
naphthyl)methyl)amino]ethanol 872710-73-1P, 2-[N-[4-
(Heptyloxy)benzyl]-N-((6-[(5-phenylpentyl)oxy]-2-
naphthyl)methyl)amino]ethanol 872710-81-1P, 2-(N-((6-[(5-
Phenylpentyl)oxy]-2-naphthyl)methyl)-N-[4-(trifluoromethoxy)benzyl]amino)e
thanol 872710-99-1P, 3-Methyl-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-00-7P, 4-Methyl-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-01-8P, 2-Chloro-N-[3-[[3-[4-(3-
phenylpropoxy)phenyl]propyl]amino]propanoyl]benzenesulfonamide
872711-02-9P, 3-Chloro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-03-0P, 4-Chloro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-04-1P, 2-Fluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-05-2P, 3-Fluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-06-3P, 4-Fluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-07-4P, N-[3-((3-[4-(3-Phenylpropoxy)phenyl]propyl)amino)pro
panoyl]-2-(trifluoromethyl)benzenesulfonamide 872711-08-5P,
N-[4-(([3-((3-[4-(3-Phenylpropoxy)phenyl]propyl)amino)propanoyl]amino)sulf
onyl)phenyl]acetamide 872711-09-6P, N-[3-((3-[4-(3-
Phenylpropoxy)phenyl]propyl)amino)propanoyl]methanesulfonamide
872711-10-9P, N-[3-((3-[4-(3-Phenylpropoxy)phenyl]propyl)amino)pro
panoyl]ethanesulfonamide 872711-11-0P, 5-Methyl-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]-2-pyridinesulfonamide
872711-12-1P, 5-Chloro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]-2-thiophenesulfonamide
872711-13-2P, N-[3-((3-[4-(3-Phenylpropoxy)phenyl]propyl)amino)pro
panoyl]-2-(trifluoromethoxy)benzenesulfonamide 872711-14-3P,
3-Cyano-N-[3-((3-[4-(3-phenylpropoxy)phenyl]propyl)amino)propanoyl]benzene
sulfonamide 872711-15-4P, N-[3-[[3-[4-(3-
Phenylpropoxy)phenyl]propyl]amino]propanoyl]-3-
(trifluoromethyl)benzenesulfonamide 872711-16-5P,
4-tert-Butyl-N-[3-((3-[4-(3-phenylpropoxy)phenyl]propyl)amino)propanoyl]be
nzenesulfonamide 872711-17-6P, N-[3-((3-[4-(3-
Phenylpropoxy)phenyl]propyl)amino)propanoyl]-4-vinylbenzenesulfonamide
872711-18-7P, 2-Methyl-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]-2-propanesulfonamide
872711-19-8P 872711-20-1P 872711-21-2P,
3-Chloro-2-methyl-N-[3-((3-[4-(3-phenylpropoxy)phenyl]propyl)amino)propano
yl]benzenesulfonamide 872711-22-3P, 3-Fluoro-4-methyl-N-[3-((3-
[4-(3-phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-23-4P, 3,5-Difluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-24-5P, 2,4-Difluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-25-6P, 2,5-Difluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-26-7P, 2,6-Difluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-27-8P, 3,4-Difluoro-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-29-0P, 2-Methoxy-4-methyl-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-30-3P, 3-Chloro-4-methyl-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-31-4P, 2,5-Dimethoxy-N-[3-((3-[4-(3-
phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide
872711-32-5P, 5-Chloro-2-fluoro-N-[3-((3-[4-(3-

phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide 872711-33-6P, 3-Chloro-2-fluoro-N-[3-((3-[4-(3-phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide 872711-34-7P, 2,6-Dichloro-N-[3-((3-[4-(3-phenylpropoxy)phenyl]propyl)amino)propanoyl]benzenesulfonamide 872711-35-8P, N-[3-((3-[4-(3-Phenylpropoxy)phenyl]propyl)amino)propanoyl]-3-thiophenesulfonamide 872711-36-9P, 5-Chloro-N-[3-((3-[4-(3-phenylpropoxy)phenyl]propyl)amino)propanoyl]-3-thiophenesulfonamide 872711-37-0P, 6-Chloro-N-[3-((3-[4-(3-phenylpropoxy)phenyl]propyl)amino)propanoyl]-3-pyridinesulfonamide 872711-38-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as sphingosine-1-phosphate (S1P) receptor agonists for prevention and/or treatment of transplant rejection, autoimmune diseases, allergic disorders, etc.)

RN 872709-26-7 CAPLUS
CN Propanamide, 3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]-N-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 872709-48-3 CAPLUS
CN Benzamide, 3-hydroxy-4-methyl-N-[2-[4-[(5-phenylpentyl)oxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 872709-50-7 CAPLUS
CN Benzamide, 3-[(E)-(hydroxyimino)methyl]-N-[2-[4-[(5-phenylpentyl)oxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 872709-51-8 CAPLUS
CN Benzamide, 3,5-bis(phenylmethoxy)-N-[2-[4-[(5-phenylpentyl)oxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 872709-52-9 CAPLUS
CN Benzamide, 3,5-dihydroxy-N-[2-[4-[(5-phenylpentyl)oxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 872709-53-0 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[(2E)-1-oxo-3-[4-(4-phenylbutoxy)phenyl]-2-propenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 872709-55-2 CAPLUS
CN 2-Propenamide, N-(2-hydroxyethyl)-3-[4-(4-phenylbutoxy)phenyl]-, (2E)-

(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 872709-57-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872709-58-5 CAPLUS
CN Pyrrolidine, 1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]- (9CI) (CA INDEX NAME)



RN 872709-59-6 CAPLUS
CN Benzenepropanamide, N-phenyl-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-60-9 CAPLUS
CN Pyrrolidine, 2-(methoxymethyl)-1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872709-61-0 CAPLUS
CN Benzenepropanamide, N-(3-acetylphenyl)-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-62-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872709-63-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N,N-dimethyl-1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872709-64-3 CAPLUS
CN Benzenepropanamide, N-(2-hydroxyethyl)-N-methyl-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-65-4 CAPLUS
CN 3-Pyrrolidinol, 1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]- (9CI) (CA INDEX NAME)



RN 872709-66-5 CAPLUS
CN Benzenepropanamide, 4-[(5-phenylpentyl)oxy]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 872709-67-6 CAPLUS

CN Benzenepropanamide, 4-[(5-phenylpentyl)oxy]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 872709-68-7 CAPLUS
CN Benzenepropanamide, N-(2-hydroxyethyl)-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-69-8 CAPLUS
CN Benzenepropanamide, N-[2-(2-hydroxyethoxy)ethyl]-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-70-1 CAPLUS
CN Benzenepropanamide, N-(3-hydroxy-4-methoxyphenyl)-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-71-2 CAPLUS
CN Benzenepropanamide, N-(3-hydroxyphenyl)-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-72-3 CAPLUS
CN Benzenepropanamide, N-(3-cyanophenyl)-4-[(5-phenylpentyl)oxy]- (9CI) (CA

INDEX NAME)



RN 872709-73-4 CAPLUS
CN Benzenepropanamide, N-[3-(aminosulfonyl)phenyl]-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-74-5 CAPLUS
CN Benzenepropanamide, N-(4-chloro-3-cyanophenyl)-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)



RN 872709-75-6 CAPLUS
CN Benzenepropanamide, N-[3-[(1E)-1-(hydroxyimino)ethyl]phenyl]-4-[(5-phenylpentyl)oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 872709-76-7 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872709-77-8 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[1-oxo-3-[4-[(5-phenylpentyl)oxy]phenyl]propyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872709-78-9 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[2-[4-[(5-phenylpentyl)oxy]phenyl]ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872709-79-0 CAPLUS
CN Pyrrolidine, 1-[[2-hydroxy-2-[4-[(5-phenylpentyl)oxy]phenyl]ethyl]sulfonyl]-2-[(phenylmethoxy)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872710-39-9 CAPLUS
CN Ethanol, 2-[[(2,4-dimethoxyphenyl)methyl][[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 872710-58-2 CAPLUS
CN Ethanol, 2-[[(4-methoxyphenyl)methyl][[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 872710-59-3 CAPLUS
CN Ethanol, 2-[[[4-(phenylmethoxy)phenyl]methyl][[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 872710-71-9 CAPLUS
CN Ethanol, 2-[[[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]methyl][[4-(2-propenyloxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 872710-72-0 CAPLUS
CN Ethanol, 2-[[[4-(octyloxy)phenyl]methyl][[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 872710-73-1 CAPLUS
CN Ethanol, 2-[[[4-(heptyloxy)phenyl]methyl][[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 872710-81-1 CAPLUS
CN Ethanol, 2-[[[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]methyl][[4-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 872710-99-1 CAPLUS
CN Propanamide, N-[(3-methylphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-00-7 CAPLUS
CN Propanamide, N-[(4-methylphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-01-8 CAPLUS
CN Propanamide, N-[(2-chlorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-02-9 CAPLUS
CN Propanamide, N-[(3-chlorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-03-0 CAPLUS
CN Propanamide, N-[(4-chlorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-04-1 CAPLUS
CN Propanamide, N-[(2-fluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-05-2 CAPLUS
CN Propanamide, N-[(3-fluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-06-3 CAPLUS

CN Propanamide, N-[(4-fluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-07-4 CAPLUS
CN Propanamide, 3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]-N-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 872711-08-5 CAPLUS
CN Propanamide, N-[[4-(acetylamino)phenyl]sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-09-6 CAPLUS
CN Propanamide, N-(methylsulfonyl)-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-10-9 CAPLUS
CN Propanamide, N-(ethylsulfonyl)-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-11-0 CAPLUS
CN Propanamide, N-[(5-methyl-2-pyridinyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-12-1 CAPLUS
CN Propanamide, N-[(5-chloro-2-thienyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-13-2 CAPLUS
CN Propanamide, 3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]-N-[[2-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 872711-14-3 CAPLUS
CN Propanamide, N-[(3-cyanophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-15-4 CAPLUS
CN Propanamide, 3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]-N-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 872711-16-5 CAPLUS
CN Propanamide, N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-3-[[3-[4-(3-

phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-17-6 CAPLUS
CN Propanamide, N-[(4-ethenylphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Ph

RN 872711-18-7 CAPLUS
CN Propanamide, N-[(1,1-dimethylethyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-19-8 CAPLUS
CN Propanamide, N-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 872711-20-1 CAPLUS
CN Propanamide, N-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 872711-21-2 CAPLUS
CN Propanamide, N-[(3-chloro-2-methylphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-22-3 CAPLUS
CN Propanamide, N-[(3-fluoro-4-methylphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-23-4 CAPLUS
CN Propanamide, N-[(3,5-difluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-24-5 CAPLUS
CN Propanamide, N-[(2,4-difluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-25-6 CAPLUS
CN Propanamide, N-[(2,5-difluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-26-7 CAPLUS
CN Propanamide, N-[(2,6-difluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-27-8 CAPLUS
CN Propanamide, N-[(3,4-difluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-29-0 CAPLUS
CN Propanamide, N-[(2-methoxy-4-methylphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-30-3 CAPLUS
CN Propanamide, N-[(3-chloro-4-methylphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-31-4 CAPLUS
CN Propanamide, N-[(2,5-dimethoxyphenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-32-5 CAPLUS
CN Propanamide, N-[(5-chloro-2-fluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-33-6 CAPLUS
CN Propanamide, N-[(3-chloro-2-fluorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-34-7 CAPLUS
CN Propanamide, N-[(2,6-dichlorophenyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-35-8 CAPLUS
CN Propanamide, 3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]-N-(3-thienylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 872711-36-9 CAPLUS
CN Propanamide, N-[(5-chloro-3-thienyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 872711-37-0 CAPLUS
CN Propanamide, N-[(6-chloro-3-pyridinyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 872711-38-1 CAPLUS
CN Propanamide, N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-3-[[3-[4-(3-phenylpropoxy)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 872709-54-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as sphingosine-1-phosphate (S1P) receptor agonists for prevention and/or treatment of transplant rejection, autoimmune diseases, allergic disorders, etc.)
RN 872709-54-1 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-phenylbutoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 872709-22-3P 872709-23-4P 872709-24-5P
872709-25-6P 872709-27-8P 872709-49-4P,
2-(4-[(5-Phenylpentyl)oxy]phenyl)ethylamine hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as sphingosine-1-phosphate (S1P)

receptor agonists for prevention and/or treatment of transplant rejection, autoimmune diseases, allergic disorders, etc.)

RN 872709-22-3 CAPLUS
CN Benzenepropanenitrile, 4-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)



RN 872709-23-4 CAPLUS
CN Benzenepropanamine, 4-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)



RN 872709-24-5 CAPLUS
CN β-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-N-[3-[4-(3-phenylpropoxy)phenyl]propyl]- (9CI) (CA INDEX NAME)



RN 872709-25-6 CAPLUS
CN β-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-N-[3-[4-(3-phenylpropoxy)phenyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 872709-27-8 CAPLUS
CN Carbamic acid, [3-oxo-3-[(phenylsulfonyl)amino]propyl][3-[4-(3-phenylpropoxy)phenyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 872709-49-4 CAPLUS
CN Benzeneethanamine, 4-[(5-phenylpentyl)oxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1171469 CAPLUS
DOCUMENT NUMBER: 143:432695
TITLE: Novel BLT2-mediated disease, and BLT2 binding agent and compound
INVENTOR(S): Nakade, Shinji; Shouno, Tomoyuki; Shimizu, Takao; Yokomizo, Takehiko; Iizuka, Yoshiko
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102388	A1	20051103	WO 2005-JP7765	20050425

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2004-129638 A 20040426
JP 2004-219533 A 20040728
OTHER SOURCE(S): MARPAT 143:432695
AB It is demanded to provide a compound capable of selective binding to

leukotriene B4 receptor BLT2 and to provide a preventive and/or therapeutic agent for cutaneous disease and other BLT2-mediated diseases. There is provided a compound having the activity of binding to BLT2, its salt or solvate, or a prodrug thereof. The compound having the activity of binding to BLT2, its salt or solvate, or a prodrug thereof, because of having the activity of binding to BLT2, is useful as a preventive and/or therapeutic agent for BLT2-mediated diseases, such as cutaneous disease, bowel disease, HIV infection, transplant rejection, transplanted organ ablation, graft-vs.-host disease, autoimmune disease, allergic disease, inflammation, infectious disease, tumor, lymphoma, malignant tumor, leukemia, arteriosclerosis, hepatitis, liver cirrhosis and cancer. For example, a compound 3'-[[(3-phenylpropanoyl)(3-phenylpropyl)amino]methyl]-1,1'-biphenyl-4-carboxylic acid sodium salt was prepared, and tested for its antagonistic effect on BLT2 in vitro. Also, a tablet containing 4'-[[pentanoyl(phenyl)amino]methyl]-1,1'-biphenyl-2-carboxylic acid 10 mg/tablet was formulated.

IT 868553-91-7P 868554-04-5P 868554-17-0P
868554-18-1P 868554-36-3P 868554-41-0P
868554-42-1P 868554-43-2P 868554-44-3P
868554-45-4P 868554-72-7P 868555-10-6P
868555-12-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(leukotriene B4 receptor BLT2-binding agents for treatment of BLT2-mediated disease)

RN 868553-91-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-[[(4-methoxybenzoyl)(3-phenylpropyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-04-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[(4-methoxybenzoyl)phenylamino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-17-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[(4-methoxybenzoyl)(phenylmethyl)am

ino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-18-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[(4-methoxybenzoyl)(3-phenylpropyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-36-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[(4-methoxybenzoyl)(3-phenylpropyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-41-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[(4-methoxybenzoyl)(4-phenylbutyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-42-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[(2,2-diphenylethyl)(4-methoxybenzoyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-43-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[[2-(1-cyclohexen-1-yl)ethyl](4-methoxybenzoyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-44-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[[[(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl](4-methoxybenzoyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 868554-45-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[(2-ethylhexyl)(4-methoxybenzoyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868554-72-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[(4-methoxyphenyl)methyl](2-phenylethyl)amino]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 868554-71-6
CMF C30 H29 N O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 868555-10-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[[(4-methoxyphenyl)methyl](2-phenylethyl)amino]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 868555-09-3
CMF C30 H29 N O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 868555-12-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[[(4-methoxyphenyl)methyl](3-phenylpropyl)amino]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 868555-11-7
CMF C31 H31 N O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:567156 CAPLUS
DOCUMENT NUMBER: 143:97350
TITLE: Preparation of aromatic compounds having carboxylic acid moiety as lysophosphatidic acid (LPA) receptor antagonists
INVENTOR(S): Tanaka, Motoyuki; Nakade, Shinji; Takaoka, Yoshikazu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058790	A1	20050630	WO 2004-JP19456	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1695955	A1	20060830	EP 2004-807811	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRIORITY APPLN. INFO.:
JP 2003-422431 A 20031219
JP 2004-101378 A 20040330
WO 2004-JP19456 W 20041217

OTHER SOURCE(S): MARPAT 143:97350
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [ring A, B = (un)substituted cycle; K, Q, M = bond, spacer; ring D, E = (un)substituted cycle; L = bond, spacer; Z = (un)protected acid group; t = 0, 1] were prepared For example, Pd-catalyzed coupling reaction of tert-Bu [[(1S,2R)-1-(3,5-dimethoxy-4-methylphenyl)-2-iodomethyl-5-phenylpentyl]oxy]dimethylsilane, e.g., prepared from (4S)-4-benzyl-1,3-oxazolidin-2-one in 6 steps, with 3-(3-iodophenyl)propanoic acid Me ester followed by exposure to tetrabutylammoniun fluoride and hydrolysis afforded compound II. In EDG-2 antagonistic activity assays, the IC50 value of compound III was 0.04 μM. Compds. I are claimed useful for the treatment of urol. disease, inflammation, etc. Formulations are given.

IT 856687-93-9P 856688-01-2P 856688-21-6P
856688-39-6P 856688-43-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic compds. having carboxylic acid moiety as lysophosphatidic acid (LPA) receptor antagonists)

RN 856687-93-9 CAPLUS
CN Acetic acid, [4-[(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)hydroxymethyl]-5-phenylpentyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856688-01-2 CAPLUS
CN Propanoic acid, 2-[4-[(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)hydroxymethyl]-5-phenylpentyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856688-21-6 CAPLUS
CN Benzeneacetic acid, 4-[(2S)-2-[(S)-[4-(difluoromethoxy)phenyl]hydroxymethyl]-5-phenylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856688-39-6 CAPLUS
CN Benzoic acid, 4-[[(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)hydroxymethyl]-5-phenylpentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856688-43-2 CAPLUS
CN Benzeneacetic acid, 4-[[(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)hydroxymethyl]-5-phenylpentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:405088 CAPLUS
DOCUMENT NUMBER: 142:463449
TITLE: Preparation of biphenylsulfonic acid derivatives as EDG receptor antagonists for treatment of inflammation
INVENTOR(S): Sato, Shin; Nakamura, Takeshi; Nara, Futoshi; Komesu, Kiyoaki
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 193 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005120047	A2	20050512	JP 2003-358892	20031020
PRIORITY APPLN. INFO.:			JP 2003-358892	20031020

OTHER SOURCE(S): MARPAT 142:463449
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [wherein R1 = H or (un)substituted alkyl; R2 = H, OH, CO2H, etc.; R3 = H, OH, aralkyloxy, etc.; X = alkylamino, OH, amino, or alkoxy; Y = CO2H, SO3H, or PO3H; Z = O, S, CO, etc.; ring A =

(un)substituted (hetero)cyclyl; ring B = (un)substituted cyclyl] or salts or esters thereof are prepared as endothelial differentiation gene (EDG) receptor antagonists for the treatment of inflammatory disease. For example, the compound II•Na was prepared in a multi-step synthesis in good yield. II•Na inhibited EDG-1 with IC50 of 0.018 μM. I are useful for the treatment of inflammation, cerebral ischemia, spasm, etc. (no data).

IT 851436-21-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biphenylsulfonic acid derivs. as EDG receptor antagonists for treatment of inflammation)

RN 851436-21-0 CAPLUS

CN [1,1'-Biphenyl]-3-sulfonic acid, 4-[(4-butoxyphenyl)thio]-2'-[hydroxy[3-[[4-(4-hydroxybutyl)phenoxy]methyl]phenyl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

IT 851437-15-5P 851437-16-6P 851437-17-7P
851437-18-8P 851437-19-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of biphenylsulfonic acid derivs. as EDG receptor antagonists for treatment of inflammation)

RN 851437-15-5 CAPLUS

CN Silane, [4-[4-[(3-bromophenyl)methoxy]phenyl]butoxy](1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)



RN 851437-16-6 CAPLUS

CN Benzenebutanol, 4-[(3-bromophenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 851437-17-7 CAPLUS
CN 2H-Pyran, 2-[4-[4-[(3-bromophenyl)methoxy]phenyl]butoxy]tetrahydro- (9CI) (CA INDEX NAME)



RN 851437-18-8 CAPLUS
CN [1,1'-Biphenyl]-3-sulfonic acid, 4-[(4-butoxyphenyl)thio]-2'-[hydroxy[3-[[4-[4-[(tetrahydro-2H-pyran-2-yl)oxy]butyl]phenoxy]methyl]phenyl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 851437-19-9 CAPLUS
CN [1,1'-Biphenyl]-3-sulfonic acid, 4-[(4-butoxyphenyl)thio]-2'-[hydroxy[3-[[4-(4-hydroxybutyl)phenoxy]methyl]phenyl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1033553 CAPLUS
DOCUMENT NUMBER: 142:38256
TITLE: Preparation of 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
INVENTOR(S): Colandrea, Vincent J.; Doherty, George A.; Hale, Jeffrey J.; Lynch, Christopher; Mills, Sander G.; Neway, William Edward, III; Toth, Leslie
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103279	A2	20041202	WO 2004-US14837	20040512
WO 2004103279	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004240586	A1	20041202	AU 2004-240586	20040512
CA 2524867	AA	20041202	CA 2004-2524867	20040512
EP 1625123	A2	20060215	EP 2004-751981	20040512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1788008	A	20060614	CN 2004-80012990	20040512
US 2006252741	A1	20061109	US 2005-554665	20051026
PRIORITY APPLN. INFO.:			US 2003-470659P P	20030515
			WO 2004-US14837 W	20040512

OTHER SOURCE(S): MARPAT 142:38256
GI



I

AB The present invention encompasses compds. of formula (I) [A = CR3 or N; D = CR4 or N; E = CR6 or N; G = CR7 or N, with the proviso that at least one of A, D, E and G is not N; X, Y, Z = N or CR8, with the proviso that at least one of X, Y and Z is not N; R1, R2 = H, C1-6 alkyl, optionally substituted with 1 to 3 halo groups; or NR1R2 together forms a 3- to 6-membered saturated monocyclic ring; R3, R4, R6, R7 = H, halo, cyano, C1-4 alkyl or C1-4 alkoxy, each optionally substituted with 1 to 3 halo groups; R5 = halo, each optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, C1-6 acyl, or aryl, heterocyclyl; or R4 and R5 may be joined together with the atoms to which they are attached to form a (un)substituted 5 or 6-membered monocyclic ring, optionally containing 1 to 3 heteroatoms selected from O, S and (un)substituted NH] as well as the pharmaceutically acceptable salts thereof. These compds. are useful for treating immune mediated diseases and conditions (imminoregulatory abnormality), such as autoimmune or chronic inflammatory disease, bone marrow, organ and tissue transplant rejection, graft-vs.-host disease, or respiratory disease or condition. They have utility as immunoregulatory agents as demonstrated by their activity as potent and selective agonists of the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor with a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor of more than 100 fold. They possessed an EC50 for binding to the S1P1/Edg1 receptor of less than 50 nM as evaluated by the [35S]GTPγS binding assay. Thus, 4-(2-methylpropyl)benzoic acid was treated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole in DMF at room for 10 min and condensed with 2-chloro-N-hydroxynicotinamidine at 120° for 3 h to give 3-[2-(Chloro)pyridin-3-yl]-5-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazole (II). II was stirred with methylamine in DMF at 120° for 16 h to give 3-[2-(methylamino)pyridin-3-yl]-5-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazole.

IT 801303-42-4P 801303-43-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (aminoazacyclyl)aryloxadiazoles as S1P receptor agonists for treating immune mediated diseases and conditions)

RN 801303-42-4 CAPLUS
CN Benzonitrile, 2-fluoro-4-[(1S)-1-methylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 801303-43-5 CAPLUS
CN Benzoic acid, 2-fluoro-4-[(1S)-1-methylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1014198 CAPLUS
DOCUMENT NUMBER: 142:713
TITLE: (1S,2R)-2-(un)substituted amino-1-aryl-1,3-propanediols as Edg receptor antagonists, their preparation, and pharmaceutical compositions containing them
INVENTOR(S): Tamai, Tadakazu; Yoshikai, Kazutaka; Nishikawa, Masazumi; Mori, Kenji
PATENT ASSIGNEE(S): Maruha Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004331523	A2	20041125	JP 2003-126209	20030501
PRIORITY APPLN. INFO.:			JP 2003-126209	20030501

OTHER SOURCE(S): MARPAT 142:713
GI



I



II

AB The title compds. I [Ar = (un)substituted aryl; R' = H, alkyl, alkylcarbonyl, alkoxy] are prepared by (1) reacting (R)-formyloxazolidines II (R = CHO; A = N-protecting group; B, C = alkyl) with ArMgBr (Ar = same as above), (2) deprotecting the resulting II [R = CH(OH)Ar; A, B, C = same as above], and (3) optionally substituting H atom of amino group of the resulting I.HCl (Ar = same as above; R' = H) with alkyl, alkylcarbonyl, or alkoxy group, converting into free bases, or forming pharmaceutically acceptable salts. Also claimed are compns. containing I or their salts for prevention or treatment of cardiovascular diseases such as arteriosclerosis and vasospasm after subarachnoid hemorrhage, rheumatoid arthritis, cancer, diabetic retinopathy, respiratory disorders, etc. Thus, I.HCl (R' = H, Ar = Ph) (III; preparation given) inhibited 2-amino-3-hydroxy-4-octadecenyl phosphate (AHOP)-induced increase in intracellular Ca2+ concentration in HL60 cells expressing Edg receptor with ED50 of 12 ± 3 nM. III also suppressed AHOP-induced vasospasm of an isolated canine basilar artery sample.
IT 796865-60-6P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (1S,2R)-2-(un)substituted amino-1-aryl-1,3-propanediols as Edg receptor antagonists for treatment of cardiovascular diseases, etc.)

RN 796865-60-6 CAPLUS

CN 1,3-Propanediol, 2-amino-1-(4-methoxyphenyl)-, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 796865-61-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (1S,2R)-2-(un)substituted amino-1-aryl-1,3-propanediols as Edg receptor antagonists for treatment of cardiovascular diseases, etc.)

RN 796865-61-7 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-[hydroxy(4-methoxyphenyl)methyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
RN 60-92-4
RN 127464-60-2
RN 7741-53-9P
RN 21829-28-7P
RN 21881-77-6P
RN 40622-01-3P
RN 66085-59-4P
RN 306764-68-1P
RN 353469-11-1P
RN 353484-05-6P
RN 524714-70-3P
RN 569656-29-7P
RN 108-38-3
RN 619-05-6
RN 1226-42-2
RN 7440-66-6
RN 7487-94-7
RN 7722-84-1
RN 76293-13-5P
RN 7440-70-2

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 40622-01-3 REGISTRY
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2,3-Bis(4-methoxyphenyl)quinoxaline-6-carboxylic acid
CN 6-Carboxy-2,3-bis(p-methoxyphenyl)quinoxaline
MF C23 H18 N2 O4
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

```
FILE 'CAPLUS' ENTERED AT 11:48:03 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:48:03 ON 15 DEC 2006

FILE 'BIOSIS' ENTERED AT 11:48:03 ON 15 DEC 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:48:03 ON 15 DEC 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s 569656-29-7/rn or 524714-70-3/rn or 353484-05-6/rn or 306764-68-1/rn or
76293-13-5/rn or dayacure rtx or rtx or 104709-02-6/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L14       3053 569656-29-7/RN OR 524714-70-3/RN OR 353484-05-6/RN OR 306764-68-
               1/RN OR 76293-13-5/RN OR DAYACURE RTX OR RTX OR 104709-02-6/RN

=> s 66085-59-4/rn or nimodipine or bay-e 9736 or nimotop or 40622-01-3/rn or
21829-28-7/rn or metanifedipine or nsc 136464 or 7741-53-9/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L15      15929 66085-59-4/RN OR NIMODIPINE OR BAY-E 9736 OR NIMOTOP OR 40622-01
               -3/RN OR 21829-28-7/RN OR METANIFEDIPINE OR NSC 136464 OR 7741-5
              3-9/RN

=> s l14 or l15 and (cancer or neoplastic or neoplas? or tumour or tumor? or
cancer? )
L16       3568 L14 OR L15 AND (CANCER OR NEOPLASTIC OR NEOPLAS? OR TUMOUR OR
               TUMOR? OR CANCER? )

=> s l16 not rtx
L17        587 L16 NOT RTX

=> dup rem l17
PROCESSING COMPLETED FOR L17
L18         417 DUP REM L17 (170 DUPLICATES REMOVED)

=> s l18 and (ovarian or peritoneal or endometrial cervical or breast or colorectal
or uterine or stomach or small intestine or thyroid)
L19          32 L18 AND (OVARIAN OR PERITONEAL OR ENDOMETRIAL CERVICAL OR BREAST
                OR COLORECTAL OR UTERINE OR STOMACH OR SMALL INTESTINE OR THYRO
               ID)

=> focus
PROCESSING COMPLETED FOR L19
L20          32 FOCUS L19 1-

=> d ibib abs 1-32 hitstr

L20  ANSWER 1 OF 32  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1998:56114  CAPLUS
DOCUMENT NUMBER:          128:97494
TITLE:                    Clinical trials of nimodipine as a potential
                          neuroprotector in ovarian cancer
                          patients treated with cisplatin
AUTHOR(S):                Cassidy, J.; Paul, J.; Soukop, M.; Habeshaw, T.; Reed,
                          N. S.; Parkin, D.; Kaye, S. B.
CORPORATE SOURCE:         Aberdeen Royal Infirmary, Aberdeen, AB25 2ZD, UK
SOURCE:                   Cancer Chemotherapy and Pharmacology (1998), 41(2),
```